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Abstract  The  guidelines  presented  herein  are  an  updated  version  of  the  recommendations
published in  2007.  Since  then,  there  has  been  a  rapid  advance  in  the  knowledge  about  the
pathophysiology  of  ulcerative  colitis  and  its  therapeutic  options.  New  drugs  have  been  approved,
novel targeted  therapies  have  emerged,  and  new  strategies  have  been  developed  to  improve
the previously  available  approaches  to  the  disease.
The aim  of  the  present  consensus  is  to  promote  the  current  knowledge  of  and  Mexican
perspective  on  the  epidemiology,  diagnosis,  and  medical  and  surgical  treatment  of  chronic
idiopathic  ulcerative  colitis.
The  final  vote  on  the  statements  and  their  ultimate  modifications  were  carried  out  at  the
consensus  working  group  meeting.  Evidence  was  evaluated  through  the  GRADE  classification.
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Consenso  mexicano  para  el  diagnóstico  y  tratamiento  de  la  colitis  ulcerosa  crónica
idiopática
Resumen  Estas  guías  constituyen  una  actualización  de  las  guías  publicadas  en  2007.  Desde
ese an˜o,  los  conocimientos  acerca  de  la  fisiopatología,  así  como  las  opciones  terapéuticas,  han
evolucionado  rápidamente,  con  la  aprobación  de  nuevos  agentes,  la  aparición  de  nuevos  blancos
terapéuticos  y  nuevas  estrategias  para  mejorar  los  abordajes  disponibles  previamente.
El objetivo  de  este  consenso  es  promover  una  actualización  y  perspectiva  mexicana  sobre  la
epidemiología,  el  diagnóstico  así  como  el  tratamiento  médico  y  quirúrgico  de  la  colitis  ulcerosa
crónica idiopática.
Los  enunciados  fueron  finalmente  votados  y  se  realizaron  las  modificaciones  finales  en  la  junta
de consenso.  La  evaluación  de  la  evidencia  por  la  clasificación  GRADE  se  realizó  al  momento
del consenso.
©  2018  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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oIntroduction
Ulcerative  colitis  (UC)  is  a  chronic  disease  of  the  colonic
mucosa  resulting  from  the  interaction  of  genetic  and  envi-
ronmental  factors.  Its  clinical  course  is  unpredictable  and
is  characterized  by  episodes  of  remission  and  relapses  or
exacerbations.  The  exact  epidemiologic  data  for  the  Mexi-
can  population  are  not  known,  but  in  recent  years,  disease
incidence  appears  to  be  on  the  rise  worldwide,  especially  in
Western  countries.1
The  present  guidelines  are  an  update  of  those  published
in  2007.2 Since  then,  there  have  been  rapid  advances  in
relation  to  the  pathophysiology  and  therapeutic  options  of
UC,  with  the  approval  of  new  agents,  new  therapeutic  tar-
gets,  and  new  strategies  to  improve  the  previously  available
approaches  to  the  disease.
Aim
To  promote  a  Mexican  perspective  on  the  epidemiology,
diagnosis,  and  medical  and  surgical  treatment  of  UC.
Methods
To  develop  the  guidelines,  Dr.  Jesús  Kazuo  Yamamoto-
Furusho  designated  a  committee  of  4  coordinators  respon-
sible  for  formulating  10  to  20  statements  related  to  the
epidemiology  and  etiopathogenesis,  diagnosis,  and  medical
and  surgical  treatment  of  UC,  from  the  most  recent  infor-
mation  on  the  disease  published  in  the  medical  literature.
A  systematic  search  of  the  literature  in  English  and
Spanish  was  carried  out  for  each  of  the  statements  for-
mulated  by  the  coordinators,  using  the  Medline/Pubmed,
Cochrane  Database  of  Systematic  Reviews,  EMBASE  (Ovid),
and  LILACS  search  engines.  The  search  strategy  included
the  following  MeSH  terms:  epidemiology,  risk  factors,  smok-
ing,  pathophysiology,  diet,  diagnosis,  serum  and  fecal
biomarkers,  fecal  calprotectin,  endoscopy,  radiology,  biop-
sies,  dysplasia,  medical  treatment,  5-aminosalicylates,
r
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wmmunomodulators, azathioprine,  cyclosporine,  steroids,
rednisone,  budesonide  MMX,  biologic  treatment,  inflix-
mab,  adalimumab,  vedolizumab.  All  the  randomized
linical  trials,  meta-analyses,  systematic  reviews,  cohort
tudies,  and  case-control  studies  published  within  the  last
0  years  (1996-2016)  were  included.
The  Mexican  Consensus  on  Ulcerative  Colitis  Working
roup  was  made  up  of  30  participants  that  included
astroenterologists,  inflammatory  bowel  disease  (IBD)  spe-
ialists,  colorectal  surgeons,  endoscopists,  and  pathologists.
he  coordinators  of  each  area  were  in  charge  of  devel-
ping  the  initial  statements.  An  online  platform  (Survey
onkey)  provided  by  Ferring  Pharmaceuticals  was  utilized
o  interview  the  participants  and  modify  the  statements
rior  to  the  final  face-to-face  vote.  A  previous  vote,  employ-
ng  the  Delphi  method,  was  carried  out  on  the  electronic
latform  to  determine  the  level  of  agreement  of  the  state-
ents.  Comments  on  specific  references  and  suggested
tatement  modifications  were  discussed.  A  final  vote  was
onducted  on  the  statements  and  the  final  modifications  of
he  statements  were  made  at  the  face-to-face  consensus
eeting.  The  quality  (or  certainty)  of  evidence  and  strength
f  recommendations  were  evaluated  through  the  Grading  of
ecommendations  Assessment,  Development  and  Evaluation
GRADE)  classification.
The  face-to-face  vote  on  the  final  statements  and
emaining  data  took  place  in  Mexico  City  in  one  day.  The
tatements  were  accepted  when  >  75%  of  the  participants
oted  4  or  5  on  a  scale  of  1  to  5.
The  recommendations  were  based  on  the  level  of  evi-
ence,  according  to  the  GRADE  classification:  Grade  A,
evel  of  evidence  1,  corresponding  to  randomized  clinical
rials;  Grade  B,  level  of  evidence  2  or  3,  corresponding
o  cohort  studies  or  case-control  studies;  Grade  C,  level
f  evidence  4,  corresponding  to  poor  quality  case  series
r  cohort  studies;  and  Grade  D,  level  of  evidence  5,  cor-
esponding  to  expert  opinion.3 The  quality  of  evidence
or  each  recommendation  was  classified  as  high,  moder-
te,  low,  or  very  low.  The  grade  of  each  recommendation
as  assigned  as  strong  (utilizing  the  term  ‘‘recommend’’)
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r  weak  (utilizing  the  term  ‘‘suggest’’).  Recommendation
trength  was  made  up  of  4  aspects:  risk/benefit  balance;
atient  preferences  and  values;  resource  availability;  and
uality  of  evidence.
Finally,  the  written  document  was  approved  by  all  the
uthors.  The  Consensus  recommendations  are  written  in
old  and  italic  fonts,  followed  by  comments  on  the  evi-
ence  supporting  the  statement.  Yamamoto-Furusho  and
utiérrez-Grobe  were  the  physicians  responsible  for  the
nal  edition  of  the  text.
. Epidemiology and etiopathogenesis
tatement  1.1.  Studies  available  in  Mexico  suggest  a
hree-fold  higher  increase  in  the  adjusted  incidence  rates
f  UC  in  the  last  twenty  years.  Agreement  percentage:  77%.
oE:  IV.  Grade  of  recommendation:  C.
Greater  incidence  and  prevalence  of  inflammatory  bowel
iseases  (IBDs)  have  been  found  in  Northern  Europe,  the
nited  Kingdom,  and  the  United  States.4 However,  an
ncrease  in  cases  of  UC  has  been  described  in  regions  of  low
ncidence,  including  Latin  America.5
In  a  study  by  Yamamoto-Furusho  published  in  2009  that
nalyzed  the  epidemiology  of  UC  in  Mexico  from  1987  to
006,  the  mean  of  new  cases  increased  from  28.8  within
he  first  period  (1987  to  1996),  to  76.1  in  the  second
eriod  (1997  to  2006).  Comparing  the  two  periods,  there
as  a  2.6-fold  increase  in  incidence.6 In  addition,  Bosques-
adilla  et  al.7,  in  their  study  published  in  2011,  found  that
he  rate  adjusted  to  the  number  of  hospital  admissions  to
he  Internal  Medicine  Service  per  year  was  2.3,  2.6,  3.0,
.6,  and  4.1/1000  admissions,  respectively,  within  the  time
rame  of  2004  to  2008,  at  a  hospital  in  Northwest  Mex-
co.
tatement  1.2.  The  greatest  incidence  peak  in  Mexico
s  in  patients  between  20  and  40  years  of  age,  equally
ffecting  men  and  women.  Agreement  percentage:  100%.
oE:  IV.  Grade  of  recommendation:  C.
In  their  study,  Bosques-Padilla  et  al.7 found  that  the  most
requent  patient  age  for  disease  presentation  was  between
he  third  and  fifth  decades  of  life.
In  his  study,  with  respect  to  age  distribution,  Yamamoto-
urusho  found  one  frequency  peak  between  21  and  30  years
f  age  (37.1%)  and  another  between  31  and  40  years  of  age
25.5%).6
tatement  1.3.  Factors  involving  the  environment,
enetics,  and  the  microbiota  interact  with  the  immune
ystem  in  UC,  resulting  in  altered  responses  that  produce
hronic  bowel  inflammation. Agreement  percentage:  97%.
oE:  IV.  Grade  of  recommendation:  C.The  key  pathophysiologic  mechanism  of  UC  is  a  dereg-
lated  immune  response  to  the  commensal  intestinal
icrobiome  in  a  genetically  susceptible  host.8 There  is
1
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ecent  evidence  that  modern  factors  that  modify  lifestyle,
uch  as  antibiotic  use,  diet,  smoking,  and  vitamin  D
etabolism,  influence  and  modify  systemic  and  intesti-
al  immunity.9 In  addition,  the  genetic  nature  of  IBDs  has
een  widely  recognized  in  different  studies,  and  today
ore  than  200  risk  alleles  have  been  identified  in  Cau-
asian  populations.  It  is  also  known  that  some  genetic
olymorphisms  act  synergically  with  the  environment  and
he  microbiota  and  that  the  pathogenesis  of  IBD  arises  from
he  interaction  between  genetic,  immunologic,  and  envi-
onmental  factors.10 In  studies  specifically  conducted  to
dentify  the  role  of  the  microbiota  in  UC,  dysbiosis  has
een  observed  to  increase  pathogenic  and  proinflammatory
acteria,  and  to  generally  be  triggered  by  an  event  such  as
nfectious  gastroenteritis,  in  which  there  is  an  imbalance
etween  commensal  bacteria  and  pathogens,  perpetuating
n  alteration  in  the  epithelial  intestinal  barrier,  causing
ranslocation  of  bacteria  and  their  products  in  genetically
usceptible  individuals.11
tatement  1.4.  Genetic  factors  are  related  to  UC
athogenesis,  explained  by  the  high  frequency  between
rst-degree  relatives  and  the  concordance  rate  found
etween  monozygotic  twins,  compared  with  dizygotic
wins.  However,  familial  aggregation  in  Mexico  is  low,
round  6.78%,  compared  with  high-incidence  popula-
ions.  Agreement  percentage:  100%.  LoE:  III.  Grade  of
ecommendation:  C.
The  authors  of  numerous  studies  have  suggested  that
enetic  factors  play  a  role  in  the  pathophysiology  of  UC.
he  sharing  of  susceptibility  genes,  as  well  as  environmen-
al  factors,  in  members  of  the  same  family,  appears  to  result
n  an  increased  risk  of  familial  aggregation  in  relation  to
BD.12 High  concordance  rates  for  monozygotic  twins,  com-
ared  with  dizygotic  twins,  have  been  reported  in  Northern
uropean  population  cohorts,  but  there  was  a  higher  risk
n  patients  with  Crohn’s  disease,  compared  with  UC.  The
oncordance  rates  for  UC  in  twins  recently  reported  in  Euro-
ean  cohorts  were  approximately  15%  for  monozygotic  twins
nd  8%  for  dizygotic  twins.13
Familial  aggregation  has  been  widely  documented  in  dif-
erent  population  studies,  ranging  from  1  to  23%,  depending
n  the  case  series  and  population.  The  familial  aggre-
ation  rate  has  been  reported  to  be  higher  in  white
atients,  than  in  those  of  other  ethnic  groups.14 In  a
exican  study,  Yamamoto-Furusho  showed  a  low  familial
requency  of  UC  of  6.78%,  compared  with  13.4  to  15%
hat  has  been  reported  in  Northern  Europe  and  the  United
tates.6
tatement  1.5.  Altered  intestinal  permeability  and  dys-
iosis  in  UC  contribute  to  antigen  exposure,  resulting  in
he  activation  of  multiple  pathways  that  induce  proin-
ammatory  cytokine  production.  Agreement  percentage:
00%.  LoE:  II.  Grade  of  recommendation:  II-B.
The  gastrointestinal  tract  contains  the  largest  micro-
ial  community  of  the  body  and  numerous  studies  have
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demonstrated  that  microbial  genes  influence  gene  expres-
sion  in  the  host.15 Increased  immunity  toward  microbial
antigens  has  been  recognized  in  UC  in  different  studies,  and
dysbiosis,  or  qualitative  and  quantitative  abnormalities  in
the  microbiota,  has  been  observed.16
Statement  1.6.  UC  is  characterized  by  the  TH2  and  TH17
helper  cell  response,  with  proinflammatory  interleukin
secretion.  Agreement  percentage:  75%.  LoE:  II,  Grade  of
recommendation:  B.
Helper  T  lymphocytes  (TH)  possess  plasticity  and  eas-
ily  adapt  to  environmental  stimuli,  which  is  necessary  for
maintaining  immunologic  homeostasis.  When  that  adaptabil-
ity  is  lost  or  altered,  restorative  changes  are  impeded,  and
the  immune  response  can  trigger  an  uncontrolled  chronic
response.9
Under  normal  circumstances,  dendritic  and  epithelial  cell
interaction  promotes  homeostasis  through  a  noninflamma-
tory  TH2  phenotype.  However,  UC  is  characterized  by  an
atypical  TH2  response,  with  uncontrolled  IL-5  and  IL-13  pro-
duction.  And  simultaneously,  mucosal  lymphocytes  produce
IL-17,  stimulating  TH17  cell  response.  The  TH17  cells  produce
multiple  cytokines,  including  IL-21  and  IL-22.  However,  the
TH17  response  is  greater  in  Crohn’s  disease  than  in  UC.9
Statement  1.7.  International  studies  show  that  active
smoking  is  not  associated  with  the  development  of  UC.
Smoking  does  not  have  a  significant  impact  on  disease
course.  Agreement  percentage:  100%.  LoE:  II.  Grade  of  rec-
ommendation:  A.
During  the  1980s,  it  was  established  that  tobacco  smokers
were  less  likely  to  develop  UC  than  nonsmokers,17 with  up
to  a  3-fold  greater  risk  for  nonsmokers,  according  to  a meta-
analysis  published  in  1989.18
The  effect  of  smoking  on  disease  course  had  not  been
determined  until  the  recent  publication  of  a  meta-analysis
with  a  systematic  review.  Its  results  showed  that  smoking
neither  improved  nor  had  a  clinical  impact  on  the  natural
history  of  UC.  Due  to  that  recent  evidence  and  the  benefi-
cial  health  effects  of  smoking  cessation,  recommending  that
patients  quit  smoking,  with  no  greater  risk  for  the  course  of
the  disease,  is  suggested.17
Statement  1.8.  Appendectomy  has  been  demonstrated
to  protect  against  UC,  perhaps  through  immunomodulat-
ing  effects.  Appendectomy  in  UC  patients  is  not  associated
with  reduced  disease  severity.  The  risk  for  colectomy  in
patients  with  UC  and  appendicitis  is  controversial.  Agree-
ment  percentage:  81%.  LoE:  III.  Grade  of  recommendation:
C.
The  authors  of  different  studies  have  observed  that  early
appendectomy  is  a  protective  factor  against  UC  develop-
ment,  suggesting  that  the  appendix  plays  a  role  in  the
pathogenesis  of  the  disease.  Nevertheless,  there  are  stud-
ies  in  which  appendectomy  performed  in  patients  older  than
20  years  of  age  was  not  protective,  suggesting  that  the
e
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ells  involved  in  UC  development  may  extend  beyond  the
ppendix  to  another  lymphoid  tissue  after  that  age.19
In  earlier  studies,  UC  was  shown  to  behave  less  severely
n  patients  after  appendectomy.20 However,  in  a  recently
ublished  meta-analysis  by  Deng  that  analyzed  6 previ-
us  studies  with  a  total  of  4,994  patients,  434  of  whom
nderwent  appendectomy,  the  results  of  a  subgroup  anal-
sis  showed  no  significant  difference  in  UC  severity  before
r  after  appendectomy,  regardless  of  disease  extension
proctitis:  OR  1.03,  95%  CI:  0.74-1.42,  p  =  0.87;  left  colitis:
R  1.01,  95%  CI:  0.73-1.39,  p  =  0.97;  pancolitis:  OR  0.92,
5%  CI:  0.59,  1.43).21
The  results  of  a  recently  published  multicenter  study
emonstrated  that  appendectomy  did  not  reduce  UC  sever-
ty,  defined  therein  as  the  need  for  total  colectomy,  when
ompared  with  patients  that  did  not  have  appendectomy.  To
he  contrary,  those  authors  reported  that  there  was  a  2.2-
old  greater  risk  for  colectomy  in  patients  that  underwent
ppendectomy  after  UC  diagnosis.21,22
tatement  1.9.  Nonsteroidal  anti-inflammatory  drugs,
ainly  naproxen,  are  associated  with  relapse  in  patients
ith  UC.  Aspirin,  COX-2,  acetaminophen,  and  nime-
ulide  have  not  demonstrated  that  association.  Oral
ontraceptives  do  not  increase  the  risk  for  disease  relapse
r  thrombosis.  Agreement  percentage:  100%.  LoE:  III.  Grade
f  recommendation:  C.
Cyclooxygenase-mediated  epithelial  barrier  disruption  in
he  intestine,  caused  by  aspirin  and  other  nonsteroidal  anti-
nflammatory  drugs  (NSAIDs)  has  been  described  to  affect
he  interaction  between  the  microbiome  and  intestinal
mmune  cells,  affecting  the  risk  for  UC  relapse.  Despite  the
ontroversial  nature  of  the  studies,  along  with  conflicting
vidence,  the  majority  have  shown  a  slight  increase  in  the
C  relapse  rate  in  NSAID  users,  and  up  to  a  2-fold  increased
isk.23
In  a  recent  cohort  study,  an  association  was  found
etween  NSAID  use  and  relapse  or  exacerbation  incidence,
articularly  in  those  patients  using  NSAIDS  for  more  than  15
ays  per  month,  not  counting  aspirin,  nimesulide,  paraceta-
ol,  and  some  COX-2  inhibitors.24 In  line  with  that,  clinical
rials  have  been  conducted  to  evaluate  the  safety  and  tol-
rability  of  the  COX-2  inhibitors,  especially  celecoxib  and
toricoxib,  in  patients  with  UC.  The  authors  of  those  stud-
es  reported  that  the  patients  taking  either  etoricoxib  or
elecoxib,  did  not  develop  significantly  more  symptoms  of
C  exacerbation,  compared  with  placebo.25--27
With  respect  to  oral  contraceptives  (OCs)  in  IBDs,  the
esults  of  a meta-analysis  of  studies  carried  out  between
980  and  2007  showed  that  current  OC  users  had  a  mini-
al,  but  statistically  significant  risk  for  exacerbation  of  UC
RR:1.28,  95%  CI:  1.26-1.70),  adjusted  for  smoking  and  other
actors.28 Nevertheless,  the  authors  of  a  systematic  review
f  5  more  recent  studies  concluded  that,  despite  the  limited
vidence,  OC  use  did  not  increase  the  risk  for  relapse  of
BDs.  However,  more  studies  on  the  subject  are  required,
iven  that  most  of  the  evidence  has  come  from  patients  with
rohn’s  disease.29
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tatement  1.10.  High  intake  of  total  fats  (>  30  g/day),
olyunsaturated  fatty  acids,  and  omega  6  fatty  acids
ppears  to  confer  a  higher  risk  for  UC.  Optimum  hygienic
onditions  apparently  influence  the  increase  of  UC.  Agree-
ent  percentage:  94%.  LoE:  IV.  Grade  of  recommendation:
.
Because  Western  populations  appear  to  be  more  affected
y  IBDs  and  the  Western  lifestyle  has  been  associated
ith  those  diseases,  the  authors  of  different  studies  have
uggested  that  high  fat  intake  is  a  risk  factor  for  developing
C.30
In  their  systematic  review,  Hou  et  al.31 found  a  sig-
ificant  association  between  a  high  total  fat  intake  and
ncreased  risk  for  UC.  Likewise,  they  observed  that  monosac-
haride  and  disaccharide  consumption  increased  the  risk  for
C.
Environmental  factors  play  an  important  role  in  the
evelopment  of  inflammatory  diseases.  First  appearing  in
n  article  in  1989,  the  ‘‘hygiene  hypothesis’’  initially
as  proposed  with  respect  to  the  inverse  correlation
etween  hay  fever  and  the  number  of  older  children  in  a
ousehold,32 and  it  appears  to  be  associated  with  different
utoimmune  diseases,  as  well  as  with  inflammatory  bowel
iseases.33
In  a  recent  meta-analysis  by  Cholapranee  and
nanthakrishnan,34 they  found  a  protective  association
etween  Crohn’s  disease  and  different  environmental
ygiene  measures,  such  as  sharing  a  bedroom,  sharing
 bed,  exposure  to  farm  animals,  having  pets,  and  hav-
ng  numerous  siblings.  The  authors  suggested  that  the
echanisms  of  those  protective  factors  included  antigenic
ompetition  and  the  influence  on  regulatory  T  cell  function,
s  well  as  modifications  in  the  gut  microbiome,  causing
reater  diversity,  and  less  susceptibility  of  the  individual  to
BDs.
. Diagnosis
tatement  2.1.  UC  is  diagnosed  through  the  correlation
f  clinical,  biochemical,  endoscopic,  and  histopathologic
spects.  Agreement  percentage:  100%.  LoE:  III.  Grade  of
ecommendation:  C.
The  natural  history  of  UC  is  characterized  by  episodes  of
elapse  and  symptom  remission.  UC  diagnosis  is  made  based
n  clinical  suspicion,  supported  by  macroscopic  endoscopic
ndings  and  typical  histologic  findings  in  the  biopsy.  Infec-
ious  agents  should  be  previously  ruled  out  in  stool  exams.35
tatement  2.2.  Chronic  diarrhea  with  mucus  and  blood,
training  and  rectal  tenesmus,  nocturnal  stools,  weight
oss,  fever,  and  abdominal  pain  are  the  most  frequent
linical  symptoms. Agreement  percentage:  100%.  LoE:  III.
rade  of  recommendation:  C.UC  is  a  chronic  inflammatory  disease  limited  to  the
olonic  mucosa,  with  a  continuous  extension  pattern  proxi-
al  from  the  rectum,  and  can  extend  throughout  the  entire
d
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olon.  Diagnosis  is  based  on  clinical  data,  obtained  from
 detailed  clinical  history  that  should  include  information
bout  the  symptoms:  symptom  onset,  presence  of  abdom-
nal  pain,  pattern  of  diarrhea,  extraintestinal  symptoms,
ectal  bleeding,  mucus  and  blood  in  stools,  symptoms  of
training  and  rectal  tenesmus,  weight  loss,  and  general  asso-
iated  symptoms,  such  as  fever.  Important  histories  include:
ygiene  conditions,  tobacco  use,  appendectomy,  antibiotic
se,  and  previous  infections.
Clinical  suspicion  must  be  supported  by  biochemical
ata,  such  as  elevated  serum  inflammation  markers,  signs
f  anemia,  elevated  fecal  markers,  and  endoscopic  and  his-
ologic  data.36
tatement  2.3.  Physical  examination  should  include  the
easurement  of  vital  signs,  such  as  blood  pressure,  heart
ate,  body  temperature,  and  weight,  as  well  as  abdominal
xamination  to  rule  out  peritoneal  irritation.  Anorectal
xamination  and  examination  of  the  eyes,  skin,  and  joints
hould  also  be  carried  out  to  search  for  extraintestinal
anifestations.  Agreement  percentage:  87%.  LoE:  IV.  Grade
f  recommendation:  C.
The  main  characteristic  of  UC  is  the  presence  of  mucus
nd  blood  in  stools,  accompanied  by  abdominal  pain.  Pain
ocation  depends  on  disease  extension.  Pain  is  gener-
lly  present  in  the  lower  left  quadrant  in  distal  disease
nd  extends  to  the  entire  colon  as  pancolitis.  Abdominal
istension  and  peritoneal  irritation  data  upon  palpation,
ccompanied  by  reduced  intestinal  noises,  require  contin-
ous  surveillance,  given  the  high  risk  for  presenting  with
oxic  megacolon.37
tatement  2.4.  A  complete  blood  count,  acute-phase
eactants  (erythrocyte  sedimentation  rate,  C-reactive
rotein),  liver  function  tests,  and  stool  tests  should  be
erformed  as  the  initial  laboratory  approach  in  patients
uspected  of  presenting  with  UC.  Agreement  percentage:
7%.  LoE:  III.  Grade  of  recommendation:  C.
Complete  blood  count,  inflammation  markers  including
-reactive  protein  (CRP)  and  erythrocyte  sedimentation  rate
ESR),  serum  electrolytes,  liver  function  tests,  and  stool
amples  for  microbiologic  analysis  should  be  ordered  for  all
atients  in  whom  UC  is  suspected.37
The  complete  blood  count  reveals  data  of  anemia,  leuko-
ytosis,  and  thrombocytosis.  Acute-phase  reactants  are
irectly  correlated  with  activity  grade,  in  addition  to  help-
ng  predict  outcomes  and  risk  for  colectomy.38 Stool  exams
hould  be  ordered  to  rule  out  frequent  pathogens,  such  as
lostridium  difficile,  which  can  be  complicating  disease  pre-
entation.
tatement  2.5.  A  complete  blood  count  to  evaluate  the
rade  of  anemia  and  an  assessment  of  iron  kinetics  to
etermine  iron  deficiency  are  suggested  during  follow-up.
greement  percentage:  90%.  LoE:  III.  Grade  of  recommen-
ation:  C.
Anemia  is  the  most  frequent  complication  in  patients
ith  inflammatory  bowel  disease,  with  an  average
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prevalence  of  18.6%  (95%  CI:  16.6-20.9).  The  majority  of
cases  are  mild-to-moderate,  with  mean  hemoglobin  of  11.3
±  0.8  g/dl.39 Anemia  is  one  of  the  main  factors  associated
with  poor  quality  of  life  in  patients  with  UC.  It  must  be
monitored,  and  its  causes  treated.  The  most  frequent  eti-
ology  of  anemia  in  UC  is  iron  deficiency,  but  it  can  also  be
caused  by  chronic  disease  anemia  or  a  combination  of  the
two.40
The  risk  for  anemia  is  related  to  UC  activity,  and  there-
fore  measurements  of  ferritin,  CRP,  and  complete  blood
count  should  be  carried  out  every  6  to  12  months  in  patients
with  mild-to-moderate  activity,  and  every  3  months  in
patients  with  active  disease.41
Statement  2.6.  Measurement  of  erythrocyte  sedimenta-
tion  rate,  C-reactive  protein,  and  fecal  calprotectin  levels
is  useful  for  evaluating  UC  activity  and  its  medical  treat-
ment  response.  Agreement  percentage:  97%.  LoE:  III.  Grade
of  recommendation:  C.
Acute-phase  serum  reactants  and  fecal  calprotectin  have
been  shown  to  be  useful  markers  for  evaluating  disease
activity  and  for  predicting  disease  outcomes.  In  the  severe
exacerbation  setting  managed  with  intravenous  steroid,  a
CRP  >  45  mg/l  at  day  3,  together  with  more  than  8  stools
per  day,  is  predictive  of  colectomy.42
Furthermore,  recent  studies  have  shown  that  fecal  cal-
protectin  is  correlated  with  endoscopic  activity  indices  and
is  useful  for  evaluating  treatment  response,  with  88%  sensi-
tivity  (95%  CI:  84-90%).43
Statement  2.7.  Perinuclear  anti-neutrophil  cytoplasmic
antibody  determination  (p-ANCA  or  its  atypical  pattern,
x-ANCA)  is  suggested  in  UC  patients,  because  it  has  been
associated  as  a  predictor  of  the  development  of  pouchi-
tis,  disease  extension,  and  extraintestinal  manifestations,
such  as  arthralgia.  Agreement  percentage:  90%.  LoE:  III.
Grade  of  recommendation:  C.
Even  though  the  usefulness  of  diagnostic  measurement
of  perinuclear  anti-neutrophil  cytoplasmic  antibodies  (p-
ANCA)  for  UC  is  low,  there  is  a  higher  prevalence  of  p-ANCA
antibodies  in  patients  with  UC  than  in  patients  with  Crohn’s
disease.  Those  antibodies  are  incubated  in  neutrophils
fixed  with  ethanol  and  analyzed  through  immunofluores-
cence.  Their  greatest  usefulness  is  in  making  the  differential
diagnosis  between  UC  and  Crohn’s  disease,  or  in  patients
with  nonspecific  inflammatory  symptoms.  In  addition,  a
higher  prevalence  of  atypical  ANCA  (x-ANCA)  than  of  p-
ANCA  has  been  observed  in  patients  with  UC  (50  vs  32%),
with  high  specificity  (96%)  and  positive  predictive  value
(99%).44,45
Some  studies  have  shown  that  the  presence  of  x-ANCA,
as  well  as  high  levels  of  p-ANCA,  are  high-risk  factors  for
developing  pouchitis,  as  well  as  predicting  disease  extension
and  the  presence  of  arthralgias.44,46
Statement  2.8.  The  genotyping  of  class  II  HLA  alleles,
such  as  HLA-DRB1*0103,  HLA-DR15,  and  HLA-DRB1*0107,
m
S
m149
as  been  associated  with  clinical  outcomes,  including
roctocolectomy,  pancolitis,  and  steroid  dependency  in
atients  with  UC.  Agreement  percentage:  97%.  LoE:  III.
rade  of  recommendation:  C.
The  genetic  role  in  susceptibility  for  UC  has  been  evalu-
ted  in  numerous  studies.  Human  leukocyte  antigen  (HLA)
s  one  of  the  genes  that  plays  a  central  role  in  immune
esponse.  The  association  between  HLA  polymorphisms  and
C  has  been  reported  in  studies  conducted  in  Japan,  the
nited  States,  and  Europe.47--50 In  their  study  on  Mexican
atients,  Yamamoto-Furusho  et  al.51 observed  increased  fre-
uency  of  HLA-DR1  polymorphisms  in  the  group  of  patients
ith  UC,  compared  with  healthy  controls  (18.7  vs  5%;  OR:
.34;  95%  CI:  1.95-9.86;  p  =  0.004).  One  of  the  associa-
ions  found  in  that  study  was  the  increased  frequency  of
LA-DR15  in  patients  with  pancolitis,  compared  with  distal
olitis  (OR:  13.53;  95%  CI:  1.4-267.4;  p  =  0.001).  Likewise,
atients  that  underwent  proctocolectomy  had  a  higher  fre-
uency  of  HLA-DRB1*0103,  compared  with  patients  that  did
ot  require  surgical  management  (OR:  6.1;  95%  CI:  1.32-
2.67).
tatement  2.9.  Fecal  calprotectin  and  fecal  lactofer-
in  levels  are  correlated  with  mucosal  cicatrization  or
ndoscopic  remission  and  are  predictors  of  UC  relapse.
greement  percentage:  97%.  LoE:  II.  Grade  of  recommen-
ation:  B.
Fecal  markers  indicate  the  presence  of  intestinal  inflam-
ation,  but  they  are  not  specific  for  IBD.  Their  greatest
sefulness  is  in  monitoring  carried  out  after  diagnosis.  Cal-
rotectin  is  a  protein  derived  from  neutrophils  and  its
xcretion  in  feces  at  very  high  cutoff  values,  especially
bove  200  mcg/g,  has  84%  sensitivity  and  96%  specificity  for
BD,  with  a  95%  positive  predictive  value.43,52
In  that  context,  the  authors  of  a  recent  meta-analysis
eported  that  there  was  78%  sensitivity  and  73%  specificity
or  predicting  relapse  in  patients  with  quiescent  IBD.53
tatement  2.10.  Ova  and  parasite  exam  with  3  sepa-
ate  stool  samples,  stool  culture,  and  Clostridium  difficile
oxin  A/B  test  are  suggested  in  cases  of  active  UC  or
elapse  to  rule  out  an  infectious  process  as  the  cause  of
isease  exacerbation. Agreement  percentage:  87%.  LoE:  III.
rade  of  recommendation:  C.
Stool  exams  should  be  performed  in  patients  with
elapse,  because  it  is  known  that  C.  difficile  and
ytomegalovirus  infections  are  associated  with  higher  mor-
ality  and  a  lack  of  treatment  response.54
In  a  study  conducted  on  a  Mexican  population,  a  61.4%
requency  of  positive  stool  exams  was  found  in  patients  with
ctive  UC.  Infection  associated  with  disease  reactivation
as  correlated  with  negative  outcomes  in  relation  to  treat-
ent  response  and  hospitalizations.55
tatement  2.11.  Plain  abdominal  x-ray  to  rule  out  toxic
egacolon  and  a  chest  x-ray  to  rule  out  colon  perforation
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hould  be  considered  in  patients  with  severe  UC.  Agree-
ent  percentage:  97%.  LoE:  III.  Grade  of  recommendation:
.
Plain  abdominal  x-ray  and  chest  x-ray  should  be  consid-
red  in  the  evaluation  of  patients  with  acute  abdominal
ain  and  computed  axial  tomography  should  be  contem-
lated  in  patients  in  whom  toxic  megacolon  or  perforation
s  suspected,  as  well  as  in  patients  with  inconclusive  bio-
hemical  tests.  Signs  of  colonic  dilation  greater  than  6  cm  in
he  transverse  colon  should  be  looked  for  when  megacolon
s  suspected.56
tatement  2.12.  The  most  widely  used  clinical  indices
or  evaluating  the  grade  of  UC  activity  are  the  Truelove
nd  Witts  index  and  the  Mayo  score. Agreement  percent-
ge:  88%.  LoE:  III.  Grade  of  recommendation:  C.
There  are  different  instruments  for  the  clinical  evalua-
ion  of  UC  activity.57 The  original  classification  system  for
evere  UC  was  proposed  by  Truelove  and  Witts  in  1955.58
t  continues  to  be  the  gold  standard  for  rapidly  identifying
atients  that  require  immediate  hospital  admission,  as  well
s  an  instrument  for  therapy  modification.45
Another  widely  used  scale  is  the  Mayo  score,  based  on  a
cale  from  0  to  12  points.  It  considers  clinical  characteris-
ics,  the  overall  evaluation  of  the  physician,  and  endoscopic
spects.  There  is  a  shorter  version  of  the  scale  that  does  not
nclude  endoscopic  data.59
Because  those  scales  provide  a  cross-sectional  evaluation
f  the  UC  patients,  meaning  at  a  single  point  in  time,  the
uture  trend  will  be  to  validate  scales  that  take  into  account
he  course  of  the  disease  and  the  grade  of  incapacity  and
ltered  quality  of  life,  among  other  important  aspects,  in
he  patient  with  UC.57
tatement  2.13.  Colonoscopy  with  ileocecal  valve  intu-
ation  is  the  diagnostic  method  of  choice  for  evaluating
he  extension  and  grade  of  disease  activity.  In  cases  of
evere  UC  activity,  only  flexible  rectosigmoidoscopy  is
ecommended  for  taking  biopsies.  Agreement  percentage:
7%.  LoE:  III.  Grade  of  recommendation:  C.
Ileocolonoscopy  with  biopsy  is  the  most  important  diag-
ostic  test  when  UC  is  suspected.  Changes  proximal  from
he  anal  verge  are  observed  and  involvement  is  characteris-
ically  continuous  and  confluent.
tatement  2.14.  The  most  characteristic  endoscopic
ndings  in  the  acute  phase  are  loss  of  the  vascular  pat-
ern,  erythema,  friability,  erosions,  and  ulcerations  of
he  mucosa.  In  the  chronic  phase,  they  are  pseudopolyps
nd  a  tubular  shape  of  the  colon.  Mucosal  compromise  is
ontinuous  in  the  majority  of  the  cases. Agreement  per-
entage:  97%.  LoE:  III.  Grade  of  recommendation:  C.Even  though  there  are  no  pathognomonic  lesions  at
ndoscopy,  lesion  aspect  tends  to  be  a  continuous  pattern
f  ulcerated  and  friable  mucosa,  with  erosions  and  vascular
attern  loss.  A  tubular  shape  of  the  colon  and  pseudopolyps
p
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f  the  mucosa  are  characteristic  of  chronic  stages.60The
ost  recent  reports  in  the  literature  suggest  the  perfor-
ance  of  colonoscopy  and  rectosigmoidoscopy  for  taking
iopsies  in  the  context  of  the  patient  with  relapse  and  the
atient  that  is  treatment-refractory.  Biopsy  is  also  suggested
or  follow-up  and  ruling  out  cytomegalovirus.
tatement  2.15.  At  least  two  biopsies  should  be  taken
er  segment  at  the  level  of  the  terminal  ileum,  ascend-
ng  colon,  transverse  colon,  descending  colon,  sigmoid
olon,  and  rectum,  including  normal  zones  of  the  mucosa,
o  microscopically  make  the  diagnosis  and  determine  dis-
ase  extension. Agreement  percentage:  93%.  LoE:  III.  Grade
f  recommendation:  C.
Multiple  biopsies  of  at  least  6  segments  of  the  colon
re  required  for  histologic  diagnosis:  the  terminal  ileum,
scending  colon,  transverse  colon,  descending  colon,  sig-
oid  colon,  and  rectum.  The  biopsies  should  be  taken  at
ndoscopically  obvious  active  and  inactive  sites.61 They
hould  be  fixed  in  formaldehyde  and  separated  by  segment
n  different  vials,  accompanied  by  the  clinical  data  of  the
atient  and  the  endoscopic  findings.
tatement  2.16.  Histopathologic  findings  suggestive  of
C  are:  crypt  architectural  distortion,  lamina  propria  lym-
hoplasmacytic  infiltrate,  cryptitis,  crypt  abscesses,  and
oblet  cell  depletion.  Agreement  percentage:  100%.  LoE:
II.  Grade  of  recommendation:  C.
Microscopic  diagnosis  of  UC  is  based  on  the  distortion  of
rypt  architecture,  diffuse  inflammatory  infiltrate  with  basal
lasmacytosis,  cryptitis  data  with  crypt  branching  and  crypt
bscesses,  as  well  as  mucin  depletion  due  to  a  reduction  of
oblet  cells.  Up  to  20%  of  patients  with  fulminant  UC  can
ave  ulcers  that  penetrate  into  the  muscularis  propria.  The
nding  of  basal  plasmacytosis  usually  helps  differentiate  UC
rom  infectious  colitis  due  to  the  frequency  of  those  cells:
3%  vs  6%,  respectively.61,62
tatement  2.17.  Dysplasia  should  be  evaluated  through
he  Vienna  classification  by  at  least  two  pathologists.
greement  percentage:  97%.  LoE:  III.  Grade  of  recommen-
ation:  C.
Dysplasia  is  defined  as  neoplastic  epithelium  with  no  signs
f  tissue  invasion  and  is  the  most  relevant  marker  for  risk
f  malignancy  in  patients  with  UC.  Dysplasia  associated  with
C  develops  in  zones  of  chronic  inflammation.  For  diagnostic
urposes,  the  use  of  the  2000  Vienna  classification  is  sug-
ested,  to  facilitate  staging  into  the  following  categories:
:  non-dysplastic  mucosa;  2:  undefined  dysplastic  lesions;  3:
ow-grade  noninvasive  neoplasia;  4:  high-grade  noninvasive
eoplasia.61
Due  to  great  interobserver  variability  in  biopsy  evalua-
ion,  it  is  suggested  that  at  least  two  expert  gastrointestinal
athologists  evaluate  the  biopsies.63
tatement  2.18.  Dysplasia  or  colorectal  cancer  surveil-
ance  in  patients  with  UC  should  be  carried  out  through
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colonoscopy  at  8  years  from  symptom  onset  in  cases  of
pancolitis,  at  12  years  from  symptom  onset  in  cases  of  left
colitis,  and  annually  from  the  diagnosis  of  primary  scleros-
ing  cholangitis. Agreement  percentage:  93%.  LoE:  Va.  Grade
of  recommendation:  D.
The  risk  of  colorectal  cancer  (CRC)  in  patients  with  UC
is  increasing,  in  comparison  with  the  general  population.
The  risk  is  associated  with  duration  and  the  grade  of  disease
activity.  The  accumulated  risk  for  CRC  has  been  reported
to  increase  from  7  to  18%  at  30  years.64,65 According  to  the
recent  literature,  surveillance  colonoscopy  has  an  impact  on
the  risk  for  CRC.66 Yearly  surveillance  colonoscopy  should  be
performed  on  patients  with  primary  sclerosing  cholangitis
from  the  time  of  diagnosis.
Statement  2.19.  Magnification  chromoendoscopy  with
indigo  carmine  or  methylene  blue  is  recommended  for
the  detection  of  flat  lesions  associated  with  dysplasia.  If
the  necessary  equipment  or  experienced  personnel  is  not
available,  biopsies  should  be  taken  in  the  four  quadrants
every  10  cm  up  to  the  descending  colon  and  every  5  cm
in  the  sigmoid  colon  and  rectum.  Agreement  percentage:
97%.  LoE:  II.  Grade  of  recommendation:  B.
The  current  recommendation  is  to  take  random  biop-
sies,  as  well  as  targeted  biopsies  in  visible  lesions,  during
white-light  colonoscopy,  but  targeted  biopsies  are  suggested
when  using  chromoendoscopy,  because  that  method  appears
to  increase  the  detection  rate  of  dysplasia.67 Chromoen-
doscopy  with  indigo  carmine  dye  improves  the  dysplasia
detection  rate,  producing  enhancement  of  subtle  vascu-
lar  and  mucosal  changes.68 The  diagnostic  yield  of  indigo
carmine  dye  is  similar  to  that  of  methylene  blue.  Neverthe-
less,  in  centers  that  lack  experience  with  chromoendoscopy,
or  that  do  not  have  the  equipment  for  the  technique,  the
suggestion  is  to  continue  screening  with  random  biopsies.  A
recent  study  suggested  that  random  biopsies  are  equally  as
efficacious  as  targeted  ones  in  detecting  neoplasia  in  endo-
scopic  surveillance.69
Statement  2.20.  Endoscopic  resection  of  the  mucosa
is  recommended  for  lesions  that  are  detected  during
follow-up  colonoscopy  and  classified  using  the  Paris  classi-
fication,  in  patients  with  UC.  Agreement  percentage:  97%.
LoE:  III.  Grade  of  recommendation:  C.
Lesion  resectability  is  the  most  important  character-
istic  in  making  therapeutic  and  surveillance  decisions
in  UC.  At  present,  the  Paris  classification  provides  a
more  simplified  way  of  classifying  UC  lesions.  In  lesions
detected  during  colonoscopy,  current  guidelines  suggest
treatment  with  endoscopic  dissection  of  the  submucosa
or  endoscopic  resection  of  the  mucosa.70 The  suggested
surveillance  interval  after  endoscopic  treatment  is  <  1
year  in  patients  with  flat  or  sessile  lesions  and  serrated
polyps  >  15  mm.  Surveillance  at  3  to  6  months  is  recom-
mended  in  patients  with  larger  lesions.  Annual  surveillance
colonoscopy  is  suggested  for  patients  with  small  polypoid
lesions.67
r
s
s
T151
.  Medical treatment
tatement  3.1.  The  5-aminosalicylates  (5-ASA)  are  the
rst  option  for  inducing  remission  in  mild-to-moderate
elapse  and  for  maintaining  remission  in  patients  with  UC.
greement  percentage:  100%.  LoE:  I.  Grade  of  recommen-
ation:  A.
Oral  5-ASA  efficacy  for  inducing  remission  in  patients
ith  active  mild-to-moderate  UC  is  supported  in  two  meta-
nalyses.  The  first  included  8  studies  and  demonstrated  a
elative  risk  (RR)  for  no  remission  of  0.86  (95%  CI:  0.81-
.91)  and  the  second  meta-analysis,  with  11  studies,  had
 RR  of  0.79  (95%  CI:  0.73-0.85).  A  dose  >  2.0  g/day  was
ore  efficacious  than  a  dose  <  2.0  g/day  (RR:  0.91;  95%  CI:
.85-0.98).71,72
tatement  3.2.  5-ASA  suppositories  at  a  dose  of  1  g  per
ay  are  recommended  as  first-line  treatment  in  patients
ith  mild-to-moderate  proctitis  (UC)  to  induce  symptom
emission.  Agreement  percentage:  93%.  LoE:  I.  Grade  of
ecommendation:  A.
A  meta-analysis  of  38  studies  on  patients  with  active
ild-to-moderate  UC  included  10  studies  in  which  rectal
-ASA  was  applied  versus  placebo.73--78 Rectal  5-ASA  was
uperior  to  placebo  for  achieving  symptom  remission  with
 RR  of  8.3  (95%  CI:  4.28-16.12;  p  <  0.00001)  and  endo-
copic  remission  with  a  RR  of  5.3  (95%  CI:  3.15-8.92;  p  <
.00001).71
The  use  of  rectal  5-ASA  was  superior  to  the  rectal  admin-
stration  of  steroids  for  inducing  symptom  remission  with  an
dds  ratio  (OR)  of  1.6  (95%  CI:  1.1-2.45;  p  <  0.01).79
tatement  3.3.  Oral  5-ASA  at  a  dose  of  2  to  4.5  g  per  day
s  recommended  as  first-line  treatment  in  patients  with
ctive  mild-to-moderate  UC  at  any  extension  beyond  that
f  proctitis  for  inducing  complete  remission.  Agreement
ercentage:  96%.  LoE:  I.  Grade  of  recommendation:  A.
Results  from  the  ASCEND  study  (n=1459)  showed  no  signif-
cant  difference  in  clinical  improvement  with  doses  of  2.4  g
r  4.8  g  per  day  of  mesalazine  in  the  overall  analysis,  but  in
he  subgroup  analysis,  the  patients  with  moderate  disease
ctivity  benefitted  from  the  higher  dose.80--82
tatement  3.4.  The  combination  of  oral  5-ASA  at  a  dose
f  2  to  4.5  g/day  and  topical  treatment  with  mesalazine  at
 dose  of  1  to  4  g/day  is  recommended  over  oral  treatment
lone  in  patients  with  active  mild-to-moderate  UC  at  any
xtension  beyond  that  of  proctitis  to  induce  remission.
greement  percentage:  84%.  LoE:  I.  Grade  of  recommenda-
ion:  A.
The  authors  of  a  meta-analysis  of  4  randomized  con-
rolled  trials  on  patients  with  active  mild-to-moderate  UC
eported  that  the  combination  of  oral  and  rectal  5-ASA  was
uperior  to  monotherapy  with  oral  5-ASA  for  inducing  remis-
ion,  with  a  RR  for  no  remission  of  0.65  (95%  CI:  0.47-0.91).
here  was  no  significant  difference  in  the  adverse  event  rate
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etween  the  patients  that  received  the  combination  ther-
py  (22.3%)  and  those  that  received  monotherapy  with  oral
-ASA  (26.9%)  (RR:  0.77;  95%  CI:  0.55-1.09).74
tatement  3.5.  Symptom  response  to  treatment  with
-ASA  in  patients  with  mild-to-moderate  UC  is  recom-
ended  to  be  evaluated  at  4-8  weeks  to  determine  the
eed  for  treatment  modification.  Agreement  percentage:
00%.  LoE:  I.  Grade  of  recommendation:  A.
The  randomized  controlled  trials  of  treatment  with  5-ASA
n  patients  with  active  UC  have  shown  that  approximately
0  to  30%  of  patients  presented  with  symptom  remission  at
reatment  week  2;  30  to  45%  at  week  4;  and  45  to  50%  at
eek  8.83,84
Almost  75%  of  the  patients  with  proctitis  or  left  colitis
ill  present  with  at  least  one  relapse  within  the  period
f  one  year,  underlining  the  importance  of  maintenance
herapy.  Meta-analyses  have  demonstrated  the  efficacy  of
aintenance  therapy  with  5-ASA  in  those  patients.85,86 In
n  analysis  of  7  randomized  controlled  trials  on  patients
reated  with  5-ASA  an  average  of  6  to  24  months,  mainte-
ance  therapy  with  rectal  5-ASA  was  associated  with  a  RR
or  relapse  of  0.60  (95%  CI:  0.49-0.73;  number  needed  to
reat  [NNT]  of  3),  compared  with  placebo.85 A  dose  of  5-
SA  >  2.0  g/day  appears  to  be  more  effective  than  a  dose
 2.0  g/day  to  prevent  a  relapse  (RR:  0.79;  95%  CI:  0.64-
.97).87
Important  clinical  differences  in  efficacy  and  safety
etween  the  different  5-ASA  formulations  for  UC  induc-
ion  and  maintenance  treatment  have  not  been  described
n  meta-analyses.  No  benefit  has  been  reported  in  switch-
ng  to  another  5-ASA  formulation  in  patients  that  have  not
chieved  remission  with  5-ASA  treatment.87,88
No  significant  difference  was  found  in  a  3-study  meta-
nalysis  in  relation  to  the  efficacy  rate  or  adherence  rate  of
nduction  treatment  with  dose  administration  once  a  day,  or
ts  fragmentation,  with  a  RR  for  no  remission  of  0.95  (95%
I:  0.82-1.1).89
There  was  no  significant  difference  in  relapse  rates  for
ingle-dose  5-ASA  or  a  regimen  2  to  3  times  a  day  in  a  meta-
nalysis  of  7  randomized  controlled  trials,  with  a  RR  of  0.94
95%  CI:  0.82-1.08).90
tatement  3.6.  Oral  budesonide  MMX  at  a  dose  of
 mg/day  is  suggested  as  alternative  treatment  in  patients
ith  mild-to-moderate  UC  at  any  extension  beyond  that
f  proctitis  to  induce  clinical  remission.  Agreement  per-
entage:  84%.  LoE:  II.  Grade  of  recommendation:  B.
Moderate-quality  studies  support  the  administration  of
udesonide  MMX  to  induce  remission  with  or  without
oncurrent  5-ASA  treatment.  In  addition,  the  formulation
ppears  to  be  safe  and  does  not  cause  adrenocortical
ysfunction.  Nevertheless,  another  moderate-quality  study
ndicated  that  5-ASA  was  superior.  Because  the  collected
vidence  is  limited,  new  studies  are  needed  to  con-
rm  its  efficacy  for  inducing  remission  in  patients  with
ild-to-moderate  UC  activity,  despite  high  doses  of  5-
SA.91
s
2
4
fJ.K.  Yamamoto-Furusho  et  al.
tatement  3.7.  Oral  systemic  steroids  are  recommended
s  second-line  treatment  to  induce  clinical  remission  in
atients  with  any  extension  of  mild-to-moderate  UC  that
ave  had  5-ASA  treatment  failure.  Agreement  percentage:
3%.  LoE:  I.  Grade  of  recommendation:  A.
Evidence  of  the  benefit  of  oral  steroid  therapy  (pred-
isone  40  mg/day)  was  that  it  induced  remission  in  76%  of
18  patients  with  mild-to-moderate  UC,  compared  with  52%
f  patients  treated  with  sulfasalazine  8  g/day.92
tatement  3.8.  Oral  corticoids  are  not  recommended  for
atients  with  UC  to  maintain  remission  because  they  are
ot  effective,  and  their  prolonged  use  is  associated  with
mportant  adverse  effects.  Agreement  percentage:  96%.
oE:  I.  Grade  of  recommendation:  A.
A  suggested  regimen  for  moderate  disease  is  prednisone
0  mg/day  or  0.5  to  1  mg/kg/day  for  4  weeks,  with  a  grad-
al  5-mg  reduction  per  week.  The  shortest  therapies  (fewer
han  3  weeks)  are  associated  with  a  high  early  relapse
ate.  The  continuous  administration  of  systemic  steroids  at
oses  above  20  mg/day  is  not  recommended  for  more  than
 months,  due  to  increased  adverse  reactions.
tatement  3.9.  Oral  steroids  are  recommended  as  first-
ine  treatment  for  inducing  remission  in  patients  with
ctive  moderate-to-severe  UC.  Agreement  percentage:
3%.  LoE:  I.  Grade  of  recommendation:  A.
The  efficacy  of  that  maneuver  has  been  documented  in
wo  controlled  studies  with  placebo  vs  conventional  steroids
n  ambulatory  patients  with  active  UC,  with  a  number
eeded  to  treat  (NNT)  of  2  (95%  CI:1.4-5).93,94 The  clini-
al  benefit  of  standard  steroids  over  placebo  for  achieving
linical  remission  of  UC  was  confirmed  in  a  meta-analysis.72
tatement  3.10.  The  evaluation  of  symptom  response  to
nduction  therapy  with  corticoids  is  recommended  after  2
eeks  to  determine  the  need  for  treatment  modification
n  patients  with  UC.  Agreement  percentage:  100%.  LoE:  I.
rade  of  recommendation:  A.
The  working  group  of  the  consensus  believes  there  should
e  a  standard  guide  to  determine  how  to  recognize  both
teroid  dependence  and  steroid  refractoriness.
tatement  3.11.  Thiopurines  are  suggested  for
orticoid-free  complete  remission  maintenance  in
atients  with  UC  that  have  achieved  symptom  remission
ith  oral  corticoids.  Agreement  percentage:  97%.  LoE:  II.
rade  of  recommendation:  B.
In  steroid-dependent  UC  patients,  both  thiopurines  and
zathioprine  are  significantly  more  effective  for  achieving
linical  and  endoscopic  remission  than  mesalazine.  In  a
tudy  in  which  72  patients  randomly  received  azathioprine
 mg/kg/day  or  oral  mesalazine  3.2  g/day  plus  prednisolone
0  mg/day,95 53%  of  the  azathioprine  group  achieved  steroid-
ree  remission  and  endoscopic  remission  after  6  months,
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compared  with  21%  of  the  mesalazine  group,  with  an  OR
of  4.78  (95%  CI:  1.57-14.5).  In  addition,  in  an  open,  obser-
vational  cohort  study  with  42  steroid-dependent  patients,
there  was  steroid-free  remission  at  12,  24,  and  36  months  in
55,  52,  and  45%  patients,  respectively.96 Thus,  thiopurines
should  be  first-line  therapy  in  patients  that  have  recurrence
after  steroid  suspension.
Statement  3.12.  Anti-TNF  is  recommended  for  inducing
complete  steroid-free  remission  in  UC  patients  that  do  not
respond  to  corticoids  or  thiopurines.  Agreement  percent-
age:  100%.  LoE:  II.  Grade  of  recommendation:  B.
In  the  ACT  1  and  2  studies,  56%  of  the  patients  were
under  treatment  with  steroids  upon  enrolling  in  the  study,97
even  though  the  dose  could  have  been  sub-optimal.  At  week
30,  a  significant  number  of  patients  that  received  infliximab
vs  placebo  achieved  steroid-free  remission  (21  vs  7%;  p  =
0.01).  At  one  year  (only  in  ACT  1),  the  rates  were  26  and
9%,  respectively  (p  =  0.006).
Statement  3.13.  Anti-TNF  therapy  for  inducing  and
maintaining  complete  steroid-free  remission  is  rec-
ommended  in  steroid-dependent  patients  with  UC.
Agreement  percentage:  96%.  LoE:  II.  Grade  of  recommen-
dation:  B.
In patients  with  steroid-dependent  or  steroid-refractory
active  UC,  other  persistent  symptom  causes  should  be
considered,  such  as  the  coexistence  of  cytomegalovirus
infection,  C.  difficile  infection,  or  cancer.  If  steroid-
dependent  or  steroid-refractory  UC  is  confirmed,  an
alternative  therapy  is  required  to  induce  steroid-free
remission.  There  is  clear  evidence  that  anti-TNF  ther-
apy  is  useful  in  that  group  of  patients.  The  ACT  1
and  ACT  2  studies  included  334/728  (46%)  patients  with
immunomodulator-refractory  disease.97 Infliximab  at  either
dose  (5  or  10  mg/kg)  provided  clinical  remission  in  a  signifi-
cantly  higher  number  of  patients  at  week  8  vs  placebo,  even
though  the  exact  number  of  subgroup  immunomodulator-
refractory  patients  was  not  reported.
Statement  3.14.  When  anti-TNF  therapy  is  begun,
monotherapy  or  combination  therapy  with  thiopurine,
depending  on  the  anti-TNF  agent  used,  is  recommended
to  induce  clinical  and  endoscopic  remission.  Agreement
percentage:  96%.  LoE:  II.  Grade  of  recommendation:  B.
In  the  UC-SUCCESS  study  on  patients  under  treatment
with  immunomodulators,  it  was  more  likely  for  the  patients
receiving  the  combination  of  azathioprine  and  infliximab
(induction  and  maintenance  therapy)  to  be  in  steroid-
free  remission  after  16  weeks,  than  the  patients  receiving
monotherapy  with  infliximab.98
According  to  a  Cochrane  group  systematic  review  of  7
trials  on  the  efficacy  of  infliximab  for  treating  steroid  or
immunomodulator-refractory  moderate-to-severe  UC,  the
conclusion  was  that  infliximab  (intravenous  infusion  at
weeks  0,  2,  and  6)  was  more  effective  than  placebo  for
inducing  clinical  remission  at  week  8,  with  a  RR  of  3.22,
i
g
i
o153
95%  CI:  2.18-4.76).99 However,  the  benefit  in  the  subgroup
f  immunomodulation  therapy-refractory  patients  was  not
eported.
At  present,  there  are  no  studies  investigating  whether  or
ot  the  combination  treatment  of  adalimumab  or  golimumab
ith  thiopurines  is  superior  to  monotherapy  in  patients  with
C.
tatement  3.15.  Evaluation  of  lack  of  symptom  response
o  induction  anti-TNF  therapy  in  UC  patients  is  recom-
ended  at  8  to  12  weeks  to  assess  the  need  for  treatment
odification.  Agreement  percentage:  100%.  LoE:  II.  Grade
f  recommendation:  B.
The  majority  of  clinical  trials  evaluate  a response  to  bio-
ogic  agents  at  the  second  week  of  treatment,  and  significant
mprovement  has  been  found  with  those  agents  between
eeks  2  and  4,  compared  with  placebo.98 Higher  remission
ates  at  week  8  have  been  reported  in  randomized  trials  that
nclude  induction  therapy,  and  they  have  been  reported  at
eek  16  in  trials  with  adalimumab.  Therefore,  when  utiliz-
ng  biologic  agents,  the  suggestion  is  to  evaluate  the  lack  of
reatment  response  at  weeks  8  to  12.100,101
We  suggest  symptom  evaluation  and  the  inclusion  of
olonoscopy,  albeit  no  ideal  time  for  its  performance  has
een  established.  Likewise,  earlier  re-evaluation  of  patients
ith  severe  UC  should  be  considered.
tatement  3.16.  The  recommendation  for  patients  that
espond  to  anti-TNF  induction  therapy  is  to  continue  with
hat  therapy  to  maintain  complete  remission.  Agreement
ercentage:  97%.  LoE:  II.  Grade  of  recommendation:  B.
Biologic  agents  were  efficacious  for  maintaining  remis-
ion  in  UC  at  one  year  of  treatment  in  35%  of  patients  vs  16%
f  patients  treated  with  placebo.98 Maintenance  of  clinical
emission  in  up  to  90%  of  patients  has  also  been  reported  in
pen  studies.102 Remission  maintenance  with  other  biologic
gents,  such  as  adalimumab,  has  been  demonstrated  in  31%
f  UC  patients  at  one-year  follow-up.103,104
A  total  of  23-28%  of  patients  treated  with  golimumab
PURSUIT)  maintained  remission  at  one  year,  compared  with
5.6%  in  the  placebo  group  (p  =  0.004).105
There  was  an  important  risk  for  opportunistic  infections
ith  the  use  of  biologic  agents  of  3%  vs  0.9%  in  patients  that
eceived  placebo,  with  a RR  of  2.05;  (95%  CI:  1.10-3.85),
nd  that  risk  tended  to  be  even  higher  with  the  combina-
ion  of  biologic  agents  plus  steroids  or  immunomodulators.
ith  adequate  prevention  measures  and  correct  screening
efore  the  administration  of  those  medications,  followed  by
eriodic  surveillance,  the  risk  for  infections,  neoplasias,  and
ther  adverse  effects  related  to  their  use  can  be  minimized
n  patients  with  UC.106
Long-term  or  indefinite  use  of  biologic  medications  in  the
atient  with  UC  is  a  controversial  theme.  Its  efficacy  in  most
eports  is  described  up  to  one  year,  but  there  is  no  opin-
on  or  consensus  on  the  subject.  Therefore,  the  working
roup  of  the  Mexican  consensus  suggests  that  their  indef-
nite  use  be  maintained,  within  the  individualized  context
f  the  patient,  until  the  medication  ceases  to  be  effective.
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percentage:  97%.  LoE:  III.  Grade  of  recommendation:  C.54  
n  a  recent  multinational,  retrospective  cohort  study,  the
uspension  of  infliximab  in  patients  with  UC  was  associated
ith  a  higher  relapse  rate  (23.3  vs  7.2  per  100  patients/year
s  7.2  of  the  control  group)  with  a  hazard  ratio  of  3.70
95%  CI:  2.02-6.77).  However,  upon  reinitiating  the  medi-
ation,  77.1%  had  treatment  response  and  51.4%  achieved
emission.107
tatement  3.17.  Dose  optimization  through  measuring
herapeutic  drug  levels  and  immunogenicity  is  recom-
ended  in  patients  with  sub-optimal  response  to  anti-TNF
herapy.  Agreement  percentage:  100%.  LoE:  II.  Grade  of
ecommendation:  B.
It  is  vital  to  know  that  there  is  a  proportional  rela-
ion  between  mucosal  healing,  induction  probability,  and
emission  maintenance  and  the  serum  biologic  agent  lev-
ls.  In  relation  to  patients  with  an  initially  inadequate
esponse,  it  is  important  to  be  aware  that  the  lack  of
esponse  during  induction  can  be  improved  through  intensi-
ying  the  dose  regimen,  which  can  be  achieved  by  shortening
he  interval  between  doses  or  increasing  the  weight-
djusted  dose,  before  considering  it  a  primary  anti-TNF
ailure.108
During  regimen  maintenance,  a  secondary  loss  can  be  the
esult  of  low  medication  levels  (45%)  or  the  formation  of
ntibodies  against  the  biologic  agent  (17%).109,110
In  patients  with  low  medication  levels,  scaling  the  dose
as  associated  with  response  in  up  to  86%  of  patients,
hereas  17%  of  patients  with  biologic  agent  antibodies
esponded.  Likewise,  dose  optimization  resulted  in  a  symp-
om  response  in  67%  of  patients  treated  with  adalimumab
hat  had  low  medication  levels.  Therefore,  dose  optimiza-
ion  should  be  considered  in  patients  with  treatment  failure,
nd  when  possible,  decisions  should  be  based  on  serum  lev-
ls  of  the  medication  and  the  presence  of  antibodies  against
t.111
tatement  3.18.  The  use  of  vedolizumab  to  induce  com-
lete  steroid-free  response,  rather  than  another  anti-TNF
rug,  is  recommended  in  patients  with  primary  anti-TNF
herapy  failure.  Agreement  percentage:  93%.  LoE:  II.  Grade
f  recommendation:  B.
In  relation  to  the  treatment  of  patients  with  conventional
iologic  treatment  failure,  despite  dose  intensification,
here  are  still  no  studies  that  directly  compare  switching
o  vedolizumab,  an  anti-integrin  molecule,  or  to  an  alterna-
ive  anti-TNF  formula.  The  available  observational  evidence
uggests  that  switching  to  a  different  anti-TNF  agent  may  be
ore  effective  in  patients  that  develop  anti-TNF  antibodies
nd  less  effective  in  patients  with  primary  failure.110,112,113
tatement  3.19.  To  induce  complete  steroid-free
emission  in  patients  with  secondary  anti-TNF  therapy
ailure,  changing  the  anti-TNF  therapy  or  switching  to
edolizumab,  based  on  the  results  of  therapeutic  drug
evel  monitoring  and  immunogenicity,  is  recommended.
greement  percentage:  100%.  LoE:  II.  Grade  of  recommen-
ation:  B. fJ.K.  Yamamoto-Furusho  et  al.
Because  the  mechanism  of  action  of  vedolizumab  is  dif-
erent  from  that  of  anti-TNF  drugs,  it  is  possible  for  that
ind  of  agent  to  be  more  effective  in  patients  with  primary
r  secondary  anti-TNF  failure.
tatement  3.20.  Vedolizumab  is  recommended  to
nduce  complete  steroid-free  remission  in  patients  with
ctive  moderate-to-severe  UC  that  present  with  steroid,
hiopurine,  or  anti-TNF  treatment  failure.  Agreement  per-
entage:  100%.  LoE:  II.  Grade  of  recommendation:  B.
During  the  induction  phase  of  the  GEMINI  I  study,
74  patients  previously  treated  with  corticosteroids,
mmunomodulators,  or  anti-TNF  therapy  were  randomly
ssigned  to  receive  vedolizumab  or  placebo.114 At  week  6,
he  vedolizumab  group  showed  superior  remission  rates,
ompared  with  the  placebo  group  (16.9%  vs  5.4%;  p<  0.001)
nd  higher  figures  in  the  failed  anti-TNF  therapy  group
9.8%  vs  3.2%),  the  steroid  group  (21.4%  vs  0%),  and  the
mmunomodulatory  group  (21.9%  vs  10.9%).114,115 The  symp-
om  response  rate  for  vedolizumab  was  also  superior  in  the
otal  population  (47.1%  vs  25.5%;  p  <  0.001),  and  in  the
roups  that  had  treatment  failure  with  anti-TNF  drugs  (39.0%
s  20.6%)  or  corticosteroids  (59.5%  vs  20.0%).115 The  consen-
us  working  group  concluded  that  vedolizumab  is  a  useful
ption  in  patients  that  have  had  prior  treatment  failure  with
orticosteroids,  immunosuppressants,  or  anti-TNF  agents.
here  are  no  available  data  on  which  strategy  to  use  in
atients  with  vedolizumab  treatment  failure,  but  an  anti-
NF  regimen  could  be  considered.  Colectomy  continues  to
e  an  option  to  contemplate  in  patients  that  do  not  respond
o  medical  therapies  or  that  have  prolonged  corticosteroid
ependence.
tatement  3.21.  The  evaluation  of  lack  of  symptom
esponse  to  induction  therapy  with  vedolizumab  in  UC
atients  is  recommended  at  8  to  14  weeks  to  determine
he  need  for  treatment  modification.  Agreement  percent-
ge:  97%.  LoE:  II.  Grade  of  recommendation:  B.
In  the  GEMINI  I  study,  vedolizumab  showed  a  statistically
ignificant  symptom  response  rate,  compared  with  placebo
t  week  6  (47.1%  vs  25.5%;  95%  CI:  11.6-31.7;  p  <  0.001).114
mprovement  in  the  partial  Mayo  score  reached  its  maximum
evel  at  week  6  and  remained  unchanged  throughout  the
aintenance  phase  and  with  minimal  change  thereafter.  The
onsensus  working  group  considers  that  in  clinical  practice,
ollow-up  evaluation  should  be  before  the  first  dose  in  the
aintenance  phase  and  recommends  that  symptom  response
e  evaluated  at  weeks  8  to  14.  That  recommendation  does
ot  exclude  early  individual  patient  evaluation,  especially
ith  respect  to  tolerance,  if  clinically  indicated.
tatement  3.22.  Apart  from  a  clinical  trial,  fecal  micro-
iota  transplantation  is  not  recommended  in  patients  with
C  to  induce  or  maintain  complete  remission.  AgreementThere  is  not  enough  evidence  to  support  the  use  of
ecal  microbiota  transplantation  (FMT)  in  patients  with  UC.
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mDiagnosis  and  treatment  of  ulcerative  colitis  
Nevertheless,  there  are  case  reports  that  suggest  its
benefit.116 The  preliminary  analysis  of  the  first  controlled
clinical  trial  of  FMT  on  63  patients  with  active  UC  did  not
show  benefits  at  week  7.117 Some  patients  reported  subjec-
tive  improvement  and  after  continuing  treatment  to  week
12,  33%  of  the  patients  achieved  complete  remission.  A
position  statement  of  the  Canadian  Association  of  Gastro-
enterology  recommended  that  in  the  absence  of  controlled
data  clearly  demonstrating  efficacy,  FMT  as  treatment  for  UC
should  only  be  used  in  the  clinical  trial  setting.116 Until  its
usefulness  is  based  on  solid  scientific  evidence,  the  present
consensus  working  group  is  against  the  use  of  FMT  in  clinical
practice.
Statement  3.23.  Apart  from  the  clinical  trial  setting,  we
do  not  recommend  probiotics  for  remission  induction  or
maintenance  in  patients  with  UC.  Agreement  percentage:
100%.  LoE:  III.  Grade  of  recommendation:  C.
In  a  meta-analysis  that  included  23  controlled  clini-
cal  trials,  probiotics,  primarily  used  as  adjuvants  in  5-ASA
management  or  immunomodulating  therapy,  significantly
increased  the  remission  rate  in  UC  patients,  with  a RR  of
1.80  (p  <  0.0001).118 That  beneficial  effect  was  apparent  only
with  VSL#3.118,119 In  another  meta-analysis  of  3  experimen-
tal  studies,  VSL#3  added  to  conventional  therapy  resulted
in  a  higher  remission  rate  than  conventional  therapy  alone
(43.8%  vs  24.8%;  OR:  2.4;  95%  CI:  1.48-3.88;  p  =  0.0001).119 A
recommendation  supporting  the  use  of  probiotics  could  not
be  made,  given  the  poor  quality  of  the  individual  studies
included  in  the  meta-analyses.
Statement  3.24.  Patients  with  severe  UC  should  be  hos-
pitalized  and  evaluated  by  experienced  physicians  for
their  optimum  treatment.  Agreement  percentage:  93%.
LoE:  Vb.  Grade  of  recommendation:  D.
Severe  UC  is  a  potentially  life-threatening  condition.  The
historic  data  on  that  clinical  setting  in  UC  show  that  47/250
(18.8%)  initial  relapses  are  severe.  In  addition,  at  least  17.6%
of  patients  are  estimated  to  have  had  a  severe  acute  episode
at  some  point  during  the  course  of  the  disease.120 The
present  consensus  working  group  believes  that  all  patients
that  meet  the  severe  UC  criteria  should  be  admitted  to  a  hos-
pital  to  receive  intensive  medical  treatment  under  the  care
of  a  multidisciplinary  team  that  includes  a  gastroenterology
specialist  and  a  colorectal  surgeon.
Statement  3.25.  Intravenous  steroids  should  be  first-line
treatment  for  patients  with  severe  UC.  Agreement  per-
centage:  100%.  LoE:  I.  Grade  of  recommendation:  A.
All  patients  admitted  with  severe  UC  require  a  thor-
ough  evaluation  that  confirms  the  diagnosis  and  rules  out  an
enteric  infection.  Intravenous  steroids  continue  to  be  the
cornerstone  of  conventional  therapy.121Statement  3.26.  Patients  that  do  not  improve  with  intra-
venous  steroids  within  the  first  72  h,  confirmed  through
clinical,  radiologic,  and  laboratory  parameters,  should  be
a
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onsidered  for  surgery  or  second-line  medical  treatment.
greement  percentage:  100%.  LoE:  II.  Grade  of  recommen-
ation:  B.
In cases  of  steroid-refractory  disease,  it  is  essential
or  alternative  rescue  treatment  options  (cyclosporine,
acrolimus,  or  infliximab)  to  be  readily  available  early  on
around  the  third  day  of  steroid  therapy),  so  that  timely
ecisions  can  be  made.  Patients  that  do  not  respond  to
edical  treatment  have  elevated  morbidity  when  surgery
s  delayed.122,123 Thus,  the  most  important  questions  con-
inue  to  be  how  to  opportunely  identify  the  patient  that  will
eed  a  colectomy  and  when  to  begin  medical  rescue  ther-
py.  The  two  alternatives  are  not  mutually  exclusive,  and
anagement  demands  careful  clinical  judgment.
.  Surgical treatment
tatement  4.1.  UC  is  a  chronic  disease  with  life-
hreatening  complications;  15-30%  of  patients  may
equire  surgical  treatment  during  the  course  of  the
isease.  Surgical  indications  are  urgent  or  elective.  Agree-
ent  percentage:  96%.  LoE:  III.  Grade  of  recommendation:
.
Much  progress  has  been  made  in  the  understanding  of  UC
nd  in  the  efficacy  of  its  different  medical  treatments,  based
n  clinical  practice  guidelines  that  enable  the  personalized
reatment  of  patients.  Said  treatment  is  supported  by  clin-
cal,  endoscopic,  laboratory,  and  imaging  monitoring  that
pportunely  indicates  the  different  responses  to  medical
reatment.  Despite  those  advances,  approximately  15-30%
f  patients  with  UC  will  require  surgical  treatment  at  some
oint  in  the  course  of  the  disease.124
Depending  on  the  clinical  scenario  of  the  patient  at  the
ime  of  deciding  upon  surgical  treatment,  the  main  indi-
ations  are  classified  as  urgent  and  elective.  The  urgent
ndications  are  medical  treatment-refractory  severe  UC,
oxic  megacolon,  perforation,  and  bleeding.  The  elective
ndications  are  refractoriness  or  adverse  reactions  to  the
ifferent  medical  treatments,  dysplasia  or  cancer,  and  the
ack  of  physical  development  in  children.125
Severe  UC  (fulminant  colitis,  toxic  colitis)  can  present
s  the  first  manifestation  of  disease  or  as  an  exacerbation
n  the  course  of  chronic  disease.  In  addition  to  severe  and
cute  inflammation  of  the  colon,  there  are  signs  of  sys-
emic  toxicity,  such  as  fluid  and  electrolyte  imbalance,
ever,  tachycardia,  reduced  hemoglobin,  and  increased  ESR
nd  CRP.  Patients  under  those  conditions  must  be  contin-
ously  monitored  to  opportunely  assess  their  response  to
edical  treatment.  If  there  is  no  early  clinical  response,
rgent  colectomy  is  the  indicated  surgical  treatment.126
oxic  megacolon  is  a  dilation  greater  than  6  cm  of  the
ransverse  colon  with  signs  of  systemic  toxicity.  It  presents
ore  frequently  in  patients  with  acute  phase  pancolitis,
nd  requires  monitoring  with  plain  abdominal  x-ray  or  CAT
can  to  decide  on  timely  surgical  treatment  that  prevents
omplications  leading  to  increased  postoperative  morbid-
ty  and  mortality,  such  as  perforation.  Perforation  occurs
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n  approximately  2%  of  the  patients  with  UC,  resulting
n  a  considerable  mortality  rate  (27-52%).  The  mortality
ate  rises  in  relation  to  the  increase  in  the  time  interval
etween  perforation  and  its  surgical  repair.  Perforation  can
resent  without  dilation  or  marked  clinical  signs  of  perit-
neal  irritation,  due  to  a  reduced  inflammatory  response
esulting  from  immunosuppressive  therapy.124,127 Patients
hat  require  surgical  treatment  should  receive  multidisci-
linary  treatment  at  hospitals  with  experience  in  IBD  and
ith  colorectal  surgeons  that  more  frequently  perform  the
urgery.128
The  main  indication  for  elective  surgery  in  the  surgical
reatment  of  UC  is  refractoriness  or  lack  of  response  to  medi-
al  treatment.  Under  such  conditions,  the  patient  does  not
chieve  profound,  sustained  disease  remission  (with  no  clin-
cal  activity  and  with  mucosal  healing)  and  is  in  a  chronically
ll  state,  malnourished,  immunosuppressed,  incapacitated,
nd  with  poor  quality  of  life  that  will  lead  to  the  devel-
pment  of  complications  if  opportune  surgical  treatment  is
ot  carried  out.129 The  presence  of  dysplasia  and  cancer  are
ther  indications  for  definitive,  elective  surgery.  With  the
evelopment  of  new  endoscopic  imaging  technologies,  sup-
orted  by  digital  or  dye-based  chromoendoscopy  (methylene
lue  or  indigo  carmine),  plus  high-definition  magnification
olonoscopy,  greater  identification  of  dysplasia  and  early
ancer  has  been  achieved.130 Today,  endoscopic  treatment
f  dysplasia  with  polypectomy  (lesions  such  as  adenomas)  or
ndoscopic  mucosal  resection  of  flat  dysplasia  is  possible.
evertheless,  there  are  reports  stating  that  such  treatment
as  not  yet  been  shown  to  be  more  effective  than  restorative
roctocolectomy  surgery.  Opportune  colectomy  in  pediatric
atients  with  delayed  physical  growth  enables  practically
ormal  development.
tatement  4.2.  Patients  with  severe  UC  require  early
urgical  assessment  and  should  be  jointly  evaluated  by  a
astroenterologist  and  colorectal  surgeon  upon  hospital
dmission  to  determine  the  opportune  time  for  surgery,
f  required.  Agreement  percentage:  96%.  LoE:  Va.  Grade  of
ecommendation:  D.
Severe  UC  is  a  critical  life-threatening  illness.  Patients
hould  always  be  hospitalized,  with  joint  surveillance  by
 gastroenterologist  and  colorectal  surgeon  to  guaran-
ee  multidisciplinary  management.125 From  the  time  of
heir  admission,  patients  should  be  informed  of  the  differ-
nt  surgical  options,  if  medical  treatment  fails.  Intensive
edical  treatment  and  continuous  clinical,  endoscopic,
aboratory,  and  imaging  monitoring  are  required  to  oppor-
unely  determine  medical  treatment  response.  From  the
urgical  viewpoint,  fluid  and  electrolyte  balance,  nutritional
upport,  and  possibly  blood  transfusions,  are  required.
lexible  sigmoidoscopy  with  biopsies  should  be  performed
o  confirm  the  diagnosis  and  rule  out  enteric  infec-
ions,  such  as  cytomegalovirus,  C.  difficile,  and  other
acteria.131 Plain  abdominal  x-ray  should  alert  the  physi-
ian  to  toxic  dilation  or  perforation,  and  an  abdominal
AT  scan  can  be  carried  out  in  cases  of  doubt.  When
ny  clinical  deterioration,  signs  of  toxicity,  or  abdominal
‘red  flags’’  (dilation  or  signs  of  peritoneal  irritation)  occur
y
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uring  medical  therapy,  colectomy  with  ileostomy  should  be
onsidered.132
tatement  4.3.  Immediate  surgical  treatment  should  be
iven  to  the  severe  UC  patient  with  progressive  deteriora-
ion  that  does  not  respond  to  initial  intravenous  therapy
3  days)  or  rescue  therapy  (7-day  maximum).  Morbidity
nd  mortality  are  increased  when  there  is a  delayed  deci-
ion  to  perform  surgery.  Agreement  percentage:  97%.  LoE:
I.  Grade  of  recommendation:  B.
Approximately  27%  of  the  patients  urgently  hospitalized
ith  UC  will  require  colectomy,  due  to  lack  of  response
o  medical  treatment  or  secondary  to  the  development
f  complications  characteristic  of  UC.  Approximately  69%
f  the  patients  with  severe  UC  will  respond  to  intra-
enous  steroids,  but  rescue  treatment  with  infliximab  or
yclosporine,  based  on  the  Oxford  criteria,  is  begun  in  more
han  56%  of  patients  that  do  not  respond  to  the  intravenous
teroid  therapy.133
Both  cyclosporine  and  anti-TNF  monoclonal  antibody
herapy  have  shown  a  mean  response  time  of  5  to  7  days  in
linical  trials.133 Urgent  colectomy  should  be  performed  in
atients  that  continue  to  present  with  symptoms  after  7  days
f  maximum  medical  treatment.133,134 There  is  a  greater
omplication  rate  when  surgery  is  required  in  patients  with
econd-line  treatment  failure  that  was  continued  for  8  days
r  more.124,129,135
Even  though  the  colon  can  be  saved  through  conservative
reatment,  unnecessary  prolongation  of  medical  treatment
hat  delays  surgery  increases  the  risk  for  postoperative
omplications  in  immunocompromised,  deteriorated,  mal-
ourished,  or  critically  ill  patients.124,134 Postoperative
ortality  in  those  patients  has  been  described  at  0.6  to
.9%.133 The  combination  of  opportune  surgery  and  inten-
ive  medical  treatment  reduces  the  mortality  rate  to  less
han  1%  in  specialized  centers.136
tatement  4.4.  Colectomy  with  end  ileostomy  is  the
urgical  procedure  of  choice  in  patients  with  medical
reatment-refractory  severe  UC,  severe  bleeding,  perfo-
ation,  or  toxic  megacolon.  A  laparoscopic  approach  is
ossible  in  stable  patients.  Agreement  percentage:  97%.
oE:  II.  Grade  of  recommendation:  B.
Close  to  15%  of  the  patients  with  UC  initially  present  with
evere  disease.137,138 Even  with  the  therapeutic  advances
ade  in  recent  decades  and  the  reduced  colectomy  rate,
urgery  continues  to  play  an  important  role  in  the  therapeu-
ic  armamentarium  of  UC,  given  that  nearly  10%  of  patients
ill  require  surgery  during  the  first  year  of  the  disease,137
nd  12-25%  will  present  with  severe  symptoms  during  the
ourse  of  the  illness.138 Approximately  27%  of  hospitalized
atients  will  require  colectomy,  due  to  a  lack  of  response
o  medical  management  or  because  of  the  development
f  complications.139 The  colectomy  rate  during  the  first  5
ears  of  the  disease  ranges  from  9  to  35%,  even  with  medi-
al  treatment.133 Opportune  surgery,  together  with  intensive
edical  treatment  has  reduced  mortality  to  less  than  1%  in
pecialized  centers.140
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Surgery  in  UC  is  divided  into  emergency/urgent  and
elective  procedures.  Emergency  surgery  is  performed  in
patients  that  present  with  toxic  megacolon,  perforation,
massive  bleeding,  sepsis,  or  fulminant  disease  unable  to
be  controlled  through  intensive  medical  treatment.134 Toxic
megacolon  is  an  acute  severe  disease  characterized  by
dilation  of  the  transverse  colon  >  6  cm,  whose  emergency
management  is  colectomy.  It  occurs  in  20  to  30%  of  patients
hospitalized  with  severe  UC.  Perforation  is  a  severe  compli-
cation  characterized  by  high  mortality  that  varies  from  27
to  57%.129
The  emergency  surgery  of  choice  in  UC  is  total  or  subto-
tal  colectomy  with  end  ileostomy.138,141 In  that  emergency
situation,  the  primary  surgical  strategy  is  diseased  colon
removal,  ileostomy  construction,  leaving  the  rectum  in  situ,
and  reduced  surgery  duration  to  prevent  progression  to  mul-
tiple  organ  failure  and  possible  death.129,139 In  the  hands
of  specialized  surgeons,  the  procedure  is  quick  and  safe
and  enables  later  reconstruction  or  restoration  of  bowel
transit.138
Rectal  stump  management  is  a  subject  of  debate.  Dis-
tal  closure  through  the  Hartmann  procedure  or  the  creation
of  a  mucosal  fistula  have  both  been  accepted.  Extrafascial
placement  of  the  distal  rectosigmoid  segment  may  be  asso-
ciated  with  minor  septic  pelvic  complications,  but  in  the
cases  in  which  the  rectal  stump  is  left  closed,  they  are
prevented  through  transrectal  drainage.124,138 The  laparo-
scopic  approach  is  a  reasonable  alternative  to  open  surgery,
and  both  procedures  have  been  shown  to  be  equally  safe.
The  laparoscopic  approach  takes  longer,  but  its  advantages
are  reduced  postoperative  pain,  more  rapid  commencement
of  stoma  function,  and  shorter  hospital  stay.140 Because
laparoscopy  is  a  less  traumatic  approach,  fewer  adhesions
are  likely  to  be  produced,  resulting  in  less  intestinal  obstruc-
tion,  which  is  one  of  the  main  postoperative  complications
in  those  patients.124
Statement  4.5.  Restorative  proctocolectomy  with  an
ileoanal  J-pouch  has  become  the  most  commonly  per-
formed  elective  surgery  in  UC  and  is  considered  the
procedure  of  choice.  Agreement  percentage:  85%.  LoE:  II.
Grade  of  recommendation:  B.
Restorative  proctocolectomy  with  an  ileoanal  pouch  (IAP)
is  currently  considered  the  criterion  standard  for  elective
surgical  treatment  of  UC.  It  has  the  advantage  of  mak-
ing  a  permanent  stoma  unnecessary,  preserving  the  natural
defecation  pathway.  There  are  several  controversial  aspects
regarding  IAP  formation,  among  which  are  the  type  of  reser-
voir  (J,  S,  or  W),  type  of  suturing  (hand-sewn  or  stapled),
the  performance  of  a  diverting  ileostomy,  and  the  type  of
surgical  approach  (open  or  laparoscopic).
Type  of  reservoir
IAP  formation,  regardless  of  the  type,  is  a  complex  surgery
and  should  be  performed  by  expert  colorectal  surgeons.  The
ileoanal  J-pouch  is  the  procedure  of  choice,  because  it  is  the
simplest  to  perform,  compared  with  the  other  types,  and  all
of  them  provide  similar  results.
a
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In  their  meta-analysis  that  included  18  studies,  with  a
otal  of  1,519  patients  with  UC  and  familial  adenomatous
olyposis  (FAP),  Lovegrove  et  al.  compared  the  short-term
nd  long-term  results  of  the  J-pouch  (689  patients),  S-pouch
524  patients),  and  W-pouch  (306  patients).  No  statisti-
ally  significant  differences  were  found  in  relation  to  the
otal  of  postoperative  complications,  anastomosis  leakage,
urgical  site  infection,  anastomosis  stricture,  pouchitis,  or
eservoir  failure.  The  patients  with  the  S-pouch  or  W-
ouch  had  a lower  number  of  defecations  in  24  h  and  less
ecessity  of  using  anti-diarrheal  agents,  compared  with
he  J-pouch.  However,  J-pouch  intubation  is  not  needed  to
chieve  defecation.142
anual  or  mechanical  reservoir
ovegrove  et  al.143 conducted  a  meta-analysis  that  included
1  studies  with  a total  of  4,183  patients  with  UC  and  FAP
hat  underwent  IAP  (2,699  hand-sewn  pouches  and  1,484
tapled  pouches).  No  significant  difference  was  found  in  the
ncidence  of  postoperative  complications  between  the  two
roups  (anastomosis  leakage:  8.8%  vs  5.2%,  p  =  0.42;  fis-
ula:  5.9%  vs  2.2%,  p  =  0.31;  pouchitis:  2.2%  vs  5%,  p  = 0.81;
tricture:  18.2%  vs  12.5%,  p  =  0.20;  pouch  failure:  5.3%  vs
.3%,  p  =  0.06).  The  stapled  pouch  had  an  improved  inci-
ence  of  nocturnal  fecal  seepage  and  pad  usage  (OR:  2.78,
<0.001  and  OR:  4.12,  p  =  0.007,  respectively).  There  was  no
tatistically  significant  difference  between  the  frequency  of
efecation  (p  =  0.562)  or  the  administration  of  anti-diarrheal
gents  (p  =  0.422).  In  relation  to  anorectal  physiology,  the
esting  and  squeezing  pressure  was  significantly  reduced  in
he  hand-sewn  pouch  group  by  13.4  and  14.4  mm  Hg,  respec-
ively  (p  <  0.018).  There  was  a  greater  incidence  of  dysplasia
n  the  anal  transition  zone,  but  it  was  not  statistically  sig-
ificant  (OR:  0.42,  p  =  0.080).
Given  the  available  surgical  evidence,  the  double-
tapling  technique,  reserving  mucosectomy  with  hand-sewn
nastomosis  for  patients  with  rectal  high-grade  dysplasia,  is
ecommended.
iverting  ileostomy
AP  can  be  carried  out  in  one,  two,  or  three  stages.  One-
tage  surgery  consists  of  forming  the  pouch  with  no  diverting
leostomy  to  avoid  a  second  surgery  and  the  consequent
orbidity  and  mortality,  as  well  as  the  adverse  effects  asso-
iated  with  the  stoma.  In  two-stage  surgery,  the  pouch  is
ormed,  leaving  a  diverting  ileostomy  in  the  segment,  to  be
losed  at  least  3  months  after  the  first  surgery  and  after
xamination  and  ruling  out  of  pouch  leaks  or  fistula.  Three-
tage  surgery  consists  of  performing  subtotal  colectomy  with
nd  ileostomy,  after  which  the  IAP  is  formed  with  a  protec-
ive  stoma,  closing  the  ileostomy  in  a  third  surgical  time.
hat  procedure  has  been  reserved  almost  exclusively  for
rgent  surgery.In  their  meta-analysis,  Weston-Petrides  et  al.144 included
 total  of  1,486  patients  in  17  comparative  studies  (765  with
o  ileostomy  and  721  with  ileostomy).  The  development  of
eakage  associated  with  the  pouch  was  significantly  higher
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n  the  group  with  no  stoma  (OR:  2.37;  p  =  0.002).  On  the
ther  hand,  the  development  of  anastomosis  stricture  (OR:
.31;  p  =  0.045)  and  pouch  failure  (OR:  0.30;  p  =  0.009)
as  significantly  lower  in  the  group  with  no  stoma.  Bowel
bstruction  was  more  common  in  the  group  with  stoma  (OR:
.37;  p=0.002).
Even  though  one-stage  surgery  in  selected  cases  (patients
ith  good  nutritional  status,  young  patients,  steroid-free
atients,  tension-free  anastomosis  with  adequate  irrigation)
as  been  proposed  in  some  studies,  two-stage  surgery  is
he  prevailing  technique  that  is  currently  in  use.  It  is  rare
or  patients  with  UC  that  are  candidates  for  surgery  not  to
ave  anastomosis  leakage  risk  factors,  and  the  two-stage
urgery  attempts  to  reduce  septic  complications  associated
ith  leakage  or  pouch  dehiscence.
tatement  4.6.  Proctocolectomy  with  definitive
leostomy  is  the  treatment  of  choice  for  UC  patients
hat  are  not  candidates  for  restorative  proctocolec-
omy.  Agreement  percentage:  97%.  LoE:  II.  Grade  of
ecommendation:  B.
Proctocolectomy  with  definitive  ileostomy  is  considered
afe,  effective,  and  potentially  curative  for  patients  with
C,  and  is  the  traditional  surgical  approach.  It  is  the  first-
ine  surgical  treatment  in  patients  that  are  not  candidates
or  restorative  surgery  and  in  patients  with  a  high  proba-
ility  of  pouch  failure.  It  can  also  be  performed  in  patients
rogrammed  for  IAP  in  whom  the  pouch  cannot  be  made  due
o  consequent  anatomic  circumstances,  such  as  the  length
f  the  mesentery.
The  patients  that  are  candidates  for  proctocolectomy
ith  definitive  ileostomy  are  those  with  sphincteric  com-
lex  lesion,  significant  previous  anoperineal  disease,  and
ow  physiologic  reserve  secondary  to  other  comorbidities.124
e  recommend  the  routine  ordering  of  anorectal  physiology
ests,  such  as  anal  manometry  and  pudendal  motor  nerve
erminal  latency  before  making  a  surgical  decision.
Although  there  are  no  prospective  studies  that  com-
are  conventional  proctectomy  (extrasphincteric)  with  the
ntersphincteric  procedure,  it  is  logical  to  suppose  that
ntersphincteric  dissection  results  in  a  smaller  wound
ith  less  probability  of  wound-associated  complications
dehiscence,  hematoma,  infection,  or  perineal  hernia).
n  addition,  because  it  is  a  benign  pathology,  the
uthors  recommend  intersphincteric  proctectomy  per-
ormed  by  a  colorectal  surgeon  that  has  mastered  the
rocedure.
Complications  related  to  this  type  of  surgery  include
tricture  or  prolapse  of  the  stoma,  bowel  obstruction,  surgi-
al  site  infection,  fistula,  persistent  pain,  delayed  perineal
ound  healing,  sexual  dysfunction,  bladder  dysfunction,  and
nfertility.  The  main  advantage  of  proctocolectomy  with
efinitive  ileostomy  over  IAP  is  that  it  prevents  the  risk  for
ouchitis,  while  offering  quality  of  life  comparable  to  that
btained  with  the  pouch.145
It  is  mandatory  to  clearly  and  thoroughly  inform  the
atient  of  the  implications,  risks,  and  benefits  of  each  of  the
urgical  alternatives  described  above,  to  make  a  responsible
s
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nd  shared  decision  in  accordance  with  his  or  her  prefer-
nces  and  expectations.
tatement  4.7.  Colectomy  with  ileorectal  anastomosis
ay  be  performed  in  a  group  of  highly  selected  patients,
s  an  alternative  to  the  ileoanal  pouch.  Agreement  per-
entage:  100%.  LoE:  II.  Grade  of  recommendation:  B.
Colectomy  with  ileorectal  anastomosis  should  be  consid-
red  only  when  rectal  inflammation  is  mild  and  has  been
ell  controlled  with  suppositories  or  mesalazine  enemas
uring  the  course  of  the  disease.146--150 It  is  important  to
linically  and  manometrically  confirm  that  the  distensibil-
ty  of  the  rectum  is  conserved,  the  patient  is  continent,
nd  there  are  no  signs  of  malignant  changes  in  the  colon
r  rectum.151,152 The  rectum  must  be  capable  of  acting
s  a reservoir.  Said  procedure  should  be  considered  if,  at
ndoscopy,  the  mucosa  is  relatively  conserved  and  there
s  distensibility  of  the  wall  upon  air  insufflation,  if  proc-
ography  reveals  similar  data,  if  manometry  is  normal
or  almost  normal),  which  is  synonymous  with  anal  conti-
ence,  and  if  there  is  no  dysplasia.153,154 Unfortunately,
ot  many  patients  meet  those  conditions.  The  presence
f  a contracted  rectum  that  does  not  carry  out  its  func-
ion  as  a  reservoir  is  a  contraindication  for  colectomy  with
leorectal  anastomosis.  Therefore,  the  appropriate  candi-
ates  for  the  procedure  are  patients  that  have  mild  rectal
isease,  adequate  distensibility  at  lower  endoscopy,  and
ith  low  risk  for  developing  rectal  cancer.146,149,152,154--158
lderly  patients  with  short  disease  duration  can  also  be
ood  candidates,  as  well  as  young  patients  that  wish  to
void  the  potential  risk  of  sexual  dysfunction  and  infer-
ility  associated  with  pelvic  dissection,  and  those  patients
hat  wish  to  return  to  normal  activities  as  soon  as  possi-
le.
The  patient  should  be  prepared  for  close  follow-up,
ue  to  the  risk  for  malignancy  in  the  remaining  rec-
al  mucosa.  Annual  rectoscopy  with  biopsies  analyzed  by
n  expert  gastrointestinal  pathologist  is  required.  If  that
s  not  possible,  then  said  technique  should  not  be  sug-
ested.
In  the  past,  before  the  introduction  of  restorative  proc-
ocolectomy,  colectomy  with  ileorectal  anastomosis  was
arried  out  in  10  to  90%  of  patients.  That  wide  range
as  the  consequence  of  preferences  and  prejudices  on  the
art  of  the  surgeons.  With  the  advent  of  restorative  proc-
ocolectomy,  the  frequency  of  colectomy  with  ileorectal
nastomosis  has  gradually  decreased.  Nevertheless,  it  con-
inues  to  have  a place  in  the  treatment  of  UC,  given  that
t  is  technically  easy  to  perform,  has  few  complications,
nd  provides  satisfactory  long-term  results  in  well-selected
ases.
tatement  4.8.  Minimally  invasive  surgery  is  safe
nd  feasible  for  elective  UC  treatment  and  has  both
hort-term  and  long-term  advantages.  The  laparoscopic
pproach  should  be  performed  in  centers  with  experi-
nce  in  the  procedure. Agreement  percentage:  94%.  LoE:
II.  Grade  of  recommendation:  C.
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rDiagnosis  and  treatment  of  ulcerative  colitis  
A  large  number  of  patients  with  UC  (20%)  still  require
surgical  procedures,  despite  the  advent  of  new  medical  and
biologic  therapies.159 Surgical  indications  in  UC  can  be  elec-
tive  (refractory  chronic  UC  and  dysplasia/cancer)  or  urgent
(acute  severe  UC).
In  1978,  Parks  and  Nicholls160 described  restorative  proc-
tocolectomy  with  ileal  pouch-anal  anastomosis  (IPAA).  It  is
the  treatment  of  choice  for  patients  with  UC  that  require
elective  surgery.160 The  2015  ECCO  guidelines  for  the  surgi-
cal  treatment  of  UC  recommend  the  J-pouch  as  standard
treatment,  because  of  its  simplicity  and  good  long-term
results.125
However,  it  has  a  high  complication  rate.  The  risk
for  infertility  is  three-fold  greater  with  the  open  surgical
technique  than  with  laparoscopy.  Minimally  invasive  laparo-
scopic  surgery  has  significantly  reduced  the  percentage  of
infertility.161,162
Surgery  of  the  colon  and  rectum  in  UC  is  currently  divided
into  pure  laparoscopic  surgery  and  hand-assisted  laparo-
scopic  surgery  (HALS).163
There  are  only  two  controlled  clinical  trials  that  compare
laparoscopic  surgery  with  open  surgery  for  the  treatment
of  UC.  In  the  first  study,  Maartense  et  al.164 included  30
patients  that  underwent  the  hand-assisted  procedure  (HALS)
versus  30  patients  that  underwent  open  surgery.  The  data
were  obtained  within  the  time  frame  of  2000-2003.  The  fol-
lowing  statistically  significant  differences  were  reported:
longer  surgery  duration  and  better  cosmetic  results  with
laparoscopy.  There  were  no  statistical  differences  in  mor-
bidity,  mortality,  or  hospital  stay  between  the  two  groups.
Laparoscopy  was  the  more  expensive  procedure.  No  cases  of
conversion  were  described.
In  2013,  Schiessling  et  al.165 compared  5-port  laparoscopy
(21  patients)  vs  open  surgery  (21  patients)  and  con-
cluded  that  the  laparoscopic  performance  of  restorative
proctocolectomy  was  feasible.  They  found  longer  surgery
duration  in  open  procedures,  better  cosmetic  results  with
laparoscopy,  and  no  statistically  significant  differences  in
relation  to  blood  loss,  hospital  stay,  bowel  function  recovery,
or  quality  of  life.165
The  Cochrane  study  contained  an  analysis  comparing
laparoscopic  IPAA  vs  open  IPAA  in  patients  with  UC  and
familial  adenomatous  polyposis.  The  authors  concluded  that
laparoscopic  IPAA  was  safe  and  feasible  in  centers  with
experience  and  offered  limited  short-term  advantages  that
included  better  postoperative  recovery.  There  were  no  dif-
ferences  between  open  IPAA  vs  laparoscopic  IPAA  regarding
frequency  of  defecation,  fecal  incontinence,  and  sexual
function.166
The  usefulness  of  laparoscopic  surgery  in  episodes  of
severe  UC  has  also  been  analyzed.  Total  colectomy  with
ileostomy  and  rectal  mucous  fistula  is  required  in  those
patients  and  they  generally  need  a  second  procedure  (two-
stage  surgery).  The  feasibility  and  safety  of  laparoscopic
surgery  in  urgent  severe  episodes  have  been  evaluated  in
studies  with  good  results.  Dunker  et  al.167 retrospectively
compared  open  surgery  versus  laparoscopy  in  42  patients
with  severe  UC  that  underwent  total  colectomy  with  rectal
mucous  fistula  and  ileostomy  and  reported  that  laparoscopic
surgery  was  safe  and  feasible  in  those  settings.
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Bartels  et  al.168 conducted  a  systematic  review  and
eta-analysis  in  the  scenario  of  severe  UC  with  a  total  of
66  patients.  Despite  the  fact  that  the  studies  analyzed
ere  retrospective,  the  rates  of  wound  infection  and  intra-
bdominal  abscess  were  significantly  lower  in  the  patients
hat  underwent  laparoscopic  surgery.
Another  advantage  of  laparoscopic  surgery  is  related  to
ertility.  It  has  been  concluded  in  several  meta-analyses  that
he  risk  for  infertility  increases  three-fold  with  open  IPAA.
he  risk  for  altering  fertility  is  thought  to  decrease  with  the
erformance  of  laparoscopic  surgery  because  fewer  adhe-
ions  (Fallopian  tube  and  pelvic  cavity  adhesions)  develop
nd  the  incisions  are  smaller.162
The  2015  ECCO  guidelines  state  that  laparoscopic  surgery
s  safe  and  feasible  for  elective  surgical  treatment  of  UC
nd  offers  better  short-term  results,  with  the  exception
f  longer  surgery  duration  and  higher  cost.  The  long-term
dvantages  are  the  formation  of  fewer  adhesions  with  pre-
erved  fertility  and  a  lower  incidence  of  hernias.125
tatement  4.9.  Restorative  proctocolectomy  is  the  pro-
edure  of  choice  in  patients  with  carcinoma  or  multifocal
igh-grade  or  low-grade  dysplasia.  Agreement  percentage:
6%.  LoE:  II.  Grade  of  recommendation:  B.
The  incidence  of  colorectal  cancer  (CRC)  in  patients  with
BD  reported  in  the  most  recent  meta-analyses  of  popula-
ion  cohorts  is  1,  2,  and  5%  after  10,  20,  and  over  20  years
f  disease  duration.169 The  reduction  in  incidence  is  due
o  the  implementation  of  endoscopic  surveillance  programs
hrough  new  techniques  of  colonoscopy  with  targeted  biopsy
nd  resection  of  suspicious  lesions,  when  possible.
Chronic  inflammation  of  the  mucosa  is  a  key  factor  in
arcinogenesis  in  patients  with  IBD.170 The  main  risk  fac-
ors  associated  with  the  development  of  malignancy  include
isease  extension  (pancolitis),  disease  duration  (more  than
 years),  disease  diagnosis  at  an  early  age,  family  his-
ory  of  IBD  or  CRC,  and  concomitant  primary  sclerosing
holangitis.124
Dysplasia  is  the  best  risk  marker  for  colorectal  can-
er  in  IBD.  Carcinogenesis  in  IBD  follows  the  sequential
nflammation  progression  from  low-grade  dysplasia  (LGD)  to
igh-grade  dysplasia  (HGD)  to  CRC.  However,  CRC  can  occur
n  a patient  with  no  history  of  dysplasia,  and  not  all  patients
ith  LGD  develop  CRC  by  way  of  HGD.170 Therefore,  LGD  can
e  considered  the  definitive  point  of  intervention  at  which
rophylactic  colectomy  for  CRC  in  patients  with  UC  should
e  performed.171 It  is  estimated  in  the  most  recent  system-
tic  reviews  that  LGD  confers  a  9%  risk  for  CRC  and  a  12%
isk  for  HGD.  In  a  meta-analysis  by  Murphy  et  al.,172 they
bserved  that  dysplasia  was  associated  with  a low  incidence
f  negative  lymph  nodes,  if  surgery  was  postponed  up  to  5
ears.
The  guidelines  of  the  International  Consensus  on  Surveil-
ance  and  Management  of  Dysplasia  in  IBD  have  very
ecently  been  published.  They  state  that  surveillance  with
olonoscopy,  rather  than  surgery,  is  indicated  after  com-
lete  endoscopic  removal  of  a  dysplastic  polypoid  lesion.
heir  recommendation  is  the  same  for  visible,  non-polypoid
ysplastic  lesions  completely  resected  through  advanced
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B60  
ndoscopic  techniques.  Colectomy  is  reserved  for  cases  of
nvisible  high-grade  dysplasia,  due  to  the  high  risk  for  CRC.67
The  finding  of  colorectal  cancer,  non-adenoma-like
ysplasia-associated  lesion  or  mass  (DALM),  or  LGD  has  been
ccepted  as  the  main  indication  for  proctocolectomy  with  or
ithout  anastomosis  (ileal  pouch-anal  anastomosis),  given
hat  there  is  concomitant  malignancy  at  the  time  of  colec-
omy  in  approximately  43  to  50%  of  cases.  The  management
f  lesions  with  flat,  unifocal  LGD  is  a  subject  of  debate,
ith  both  endoscopic  surveillance  and  total  proctocolec-
omy  being  suggested.  The  decision  should  be  made  with  the
atient,  explaining  the  risks  involved  in  endoscopic  surveil-
ance  versus  those  of  surgery  and  the  possible  development
f  HGD  or  CRC.124
Restorative  proctocolectomy  with  ileal  pouch-anal  anas-
omosis  (RPC-IPAA)  is  the  standard  procedure  in  patients
ith  UC.  The  rectal  mucosa  is  completely  resected,  thus
liminating  the  risk  for  the  future  development  of  carcinoma
n  the  rectal  remnant.  Colectomy  in  patients  with  dysplasia
r  carcinoma,  requires  sufficient  lymph  node  resection  with
obilization  of  the  mesentery  and  high  vascular  ligature.173
tatement  4.10.  Surveillance  or  follow-up  of  the  ileo-
nal  pouch  is  not  necessary  in  the  asymptomatic  patient,
nless  there  are  risk  factors,  such  as  a  history  of  neoplasia
r  primary  sclerosing  cholangitis. Agreement  percentage:
7%.  LoE:  III.  Grade  of  recommendation:  C.
In  general,  the  follow-up  of  patients  with  ileo-anal  pouch
s  controversial.  There  is  no  evidence  suggesting  that  the
ack  of  follow-up  results  in  any  risk  for  the  patient,  except
he  debatable  risk  for  cancer.  Follow-up  should  be  indi-
idualized  in  accordance  with  the  characteristics  of  each
atient.  No  specific  follow-up  protocol  is  required  in  asymp-
omatic  patients  with  no  risk  factors  (history  of  neoplasia
r  primary  sclerosing  cholangitis).125 Pouch  follow-up  is
ecommended  in  symptomatic  patients.  Clinical  signs  and
ymptoms  of  inflammation  of  the  ileo-anal  pouch,  such  as
n  increased  number  of  defecations,  the  presence  of  mucus
nd  blood,  tenesmus,  fever,  or  pelvic  pain,  should  alert  the
hysician  to  perform  diagnostic  and  treatment  follow-up.
he  presence  of  symptoms  related  to  pouch  complications,
uch  as  incontinence  or  obstructive  signs,  or  perianal  alter-
tions,  such  as  the  presence  of  fistulas  or  stricture,  also
equires  diagnostic  follow-up  carried  out  by  experienced
pecialists,  for  successful  diagnosis  and  treatment.174
There  is  not  enough  evidence  available  to  make  recom-
endations  about  ileo-anal  pouch  surveillance,  with  respect
o  malignant  changes.  However,  high-risk  patients,  such  as
hose  with  primary  sclerosing  cholangitis,  a  rectal  rem-
ant  longer  than  2  cm,  type  C  mucosa  (permanent  mucosal
trophy  and  severe  inflammation),  or  previous  malignancy
r  dysplasia  should  have  long-term  follow-up  for  dysplasia
urveillance  of  the  pouch  or  rectal  remnant.131 Approxi-
ately  30  pouch  cancers  have  been  reported,  all  of  themn  patients  that  were  operated  on  for  dysplasia  or  cancer
n  the  surgical  specimen  of  the  first  surgery.  Despite  their
mall  number,  attention  must  be  focused  on  those  high-risk
atients.175
a
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In  a  systematic  review  of  dysplasia  or  cancer  after
estorative  proctocolectomy,  even  when  the  surgical  indi-
ation  had  been  for  dysplasia  or  cancer,  the  risk  for  newly
eveloping  dysplasia  or  cancer  in  the  rectal  remnant  or
ouch  was  very  low.  The  prevalence  of  high-grade  dysplasia,
ow-grade  dysplasia,  or  undefined  dysplasia  was  0.15  (range:
.4-49),  0.98  (range:  0-15.62)  and  1.23%  (range:  0-25.28%),
espectively.176 Dysplasia  was  equally  frequent  in  the  pouch,
ectal  remnant,  or  anal  transition  zone.  Dysplasia  diagnosed
efore  or  during  surgery  appears  to  be  a  significant  predictor
or  the  development  of  dysplasia  in  the  pouch.177
Annual  surveillance  in  high-risk  patients  and  every  5  years
n  low-risk  patients  appears  to  be  reasonable.178
tatement  4.11.  Early  endoscopic  revision  of  the  reser-
oir  is  recommended  in  symptomatic  patients  to  identify
ouchitis  (inflammation  of  the  reservoir),  cuffitis  (inflam-
atory  disease  activity  in  the  rectal  remnant),  and  other
dded  alterations. Agreement  percentage:  97%.  LoE:  III.
rade  of  recommendation:  C.
Pouchitis  (pouch  inflammation)  is  the  most  common
omplication  and  occurs  in  more  than  50%  of  patients  at  10
ears.  Extensive  UC,  the  presence  of  extraintestinal  man-
festations,  mainly  primary  sclerosing  cholangitis,  being  a
onsmoker,  high  preoperative  levels  of  p-ANCA,  and  steroid
nd  NSAID  use  are  considered  risk  factors  for  developing
ouchitis.46
The  clinical  diagnosis  of  pouchitis  is  made  when  there  is
n  increase  in  the  number  of  defecations,  urgency,  abdom-
nal  cramps,  and  incontinence.  Nevertheless,  diagnosis  is
ot  simple.  It  requires  the  combined  evaluation  of  symp-
oms,  endoscopic  findings,  and  histologic  characteristics.179
he  most  frequently  used  method  for  the  diagnosis  and
lassification  of  pouchitis  is  the  18-point  Pouchitis  Activity
ndex,  based  on  the  evaluation  of  symptoms,  endoscopy,
nd  histology.  Diagnosis  is  made  through  the  index  when
here  are  clinical  symptoms  of  diarrhea  >  6  defecations/day,
ndoscopic  findings  >  4  signs  (edema,  granularity,  friability,
oss  of  submucosal  vascular  pattern,  bleeding  or  ulcera-
ion),  and  histopathologic  alterations:  a  minimum  score  of  4
n  a 6-point  index  (polymorphic  nuclear  leukocyte  infiltra-
ion  and  percentage  of  ulceration  in  a  low  power  field).180
ndoscopy  is  the  best  method  for  diagnosing  pouchitis  and
ifferentiating  other  pathologies,  such  as  cuffitis  (active
nflammation  of  the  rectal  remnant),  stricture,  anastomo-
is  leakage,  ischemia,  irritable  pouch  syndrome,  fistulas  and
bscesses,  Crohn’s  disease,  cytomegalovirus,  C.  difficile,
ysplasia,  and  cancer.181,182
tatement  4.12.  First-line  treatment  in  patients  with
cute  pouchitis  is  500  mg  of  ciprofloxacin  twice  a  day
r  15-20  mg/kg/day  of  metronidazole  for  2  weeks.  Agree-
ent  percentage:  96%.  LoE:  II.  Grade  of  recommendation:
.Acute  pouchitis  in  its  initial  stages  responds  well  to
ntibiotic  therapy.  Surgical  complications,  such  as  anasto-
osis  leakage  or  fistula,  should  be  suspected  in  patients
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with  symptoms  of  pouchitis  immediately  after  the  construc-
tion  of  the  reservoir  and  closure  of  the  diverting  ileostomy,
and  in  patients  that  do  not  respond  to  antibiotic  therapy.
Few  randomized,  placebo-controlled  trials  on  the  treat-
ment  and  prevention  of  pouchitis  have  been  published.  In
clinical  practice,  metronidazole,  ciprofloxacin,  tinidazole,
and  rifaximin  have  been  used  in  the  treatment  of  acute
pouchitis.183,184 First-line  therapy  includes  a  regimen  of  14
days  of  metronidazole  (15-20  mg/kg/day)  or  ciprofloxacin
(1  g/day).  Side  effects  are  less  frequent  with  ciprofloxacin.
Other  antibiotics  have  been  studied  and  proved  to  be  effec-
tive  in  some  patients  in  small  studies,  and  they  include
tinidazole,  rifaximin,  and  amoxicillin-clavulanic  acid.185
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